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1 Introduction 
1.1 Coronaviridae 
Coronaviruses contain the largest single-stranded positive-sense RNA genome of any known 
virus family to date. The genome size varies from 27-32 kilobase pairs (kb). The spherical 
enveloped virions measure 120 to 160 nm in diameter. Prominent spike proteins on the 
surface of the virions lead to a morphology resembling a crown (lat: corona) when examined 
by electron microscopy. Therefore the first viruses discovered in this family were named 
“Coronavirus”. Every coronavirus genome contains five major open reading frames (ORFs). 
These encode the replicase polyprotein, the spike (S), envelope (E), and membrane (M) 
glycoproteins; and the nucleocapsid protein (N) (see Figure 1). 
 
Figure 1: Coronavirus model (left) and electron micrograph of human coronavirus NL63 (HCoV-NL63, 
right). Left: a coronavirus model showing the organization of the spike (S), membrane (M) and envelope (E) 
glycoproteins, as well as the RNA and helical nucleocapsid (N) arrangement. Model from (Holmes et al. 2003). 
Right: an electron micrograph of HCoV-NL63 with prominent spike proteins giving the particles a crown-like 
appearance (van der Hoek et al. 2006). 
1.1.1 Taxonomy 
The human coronavirus NL63 (HCoV-NL63) belongs to the family of Coronaviridae which 
comprises two subfamilies, the Coronavirinae and the Torovirinae. Together with the 
Roniviridae and the Arteriviridae the Coronaviridae belong to the order Nidovirales. With the 
2011 release of the International Committee on Taxonomy of Viruses (ICTV) the 
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Coronavirinae are subdivided in four genera, the Alpha-, Beta-, Gamma-, and 
Deltacoronaviruses (see Figure 2).  
 
 
Figure 2: Phylogenetic relationships among the members of the subfamily Coronavirinae. A rooted 
Neighbour-Joining tree was generated from amino acid sequence alignments of RdRp and helicase domains with 
equine torovirus Berne as outgroup. The tree reveals four main monophyletic clusters corresponding to genera 
Alpha-, Beta- and Gammacoronavirus and an envisaged new genus Deltacoronavirus (color-coded). From the 
proposal “A new genus and three new species in the subfamily Coronavirinae“(2010.023a-dV) to the ICTV by 
Raoul J. de Groot and Alexander E. Gorbalenya. 
1.1.1.1 Alphacoronavirus 
The genus Alphacoronavirus contains two human coronavirus species, the long known 
HCoV-229E (Hamre et al. 1966) and the recently discovered HCoV-NL63 (van der Hoek et 
al. 2004). With the porcine epidemic diarrhea virus (PEDV) (Wood 1977; Chasey et al. 1978; 
Pensaert et al. 1978; Hofmann et al. 1988; Kusanagi et al. 1992) and the transmissible 
gastroenteritis virus (TGEV) (Bohl et al. 1972; Bohl et al. 1972; Saif et al. 1972; Garwes 
1988; Enjuanes et al. 1995; Kim et al. 2000) it further contains coronaviruses that had an 
economic impact on agriculture due to high mortality rates in piglets. Vaccination against 
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TGEV reduced the losses in pig farms by TGEV, but suddenly uprising PEDV (Shibata et al. 
2000) epidemics in north America showed similar symptoms and economic impact.  
Other viruses closely related to TGEV and also affecting domestic animals are the feline and 
canine coronaviruses (FCoV, CCoV). Due to their high sequence identity (>96% sequence 
identity within the replicase polyprotein pp1ab) TGEV, FCoV and CCoV are grouped into the 
type species alphacoronavirus 1, formerly known as subgroup 1a (Gonzalez et al. 2003) (see 
Figure 2). They cause mainly mild gastroenteritis but in case of FCoV a spontaneous 
mutation in vivo can cause the highly lethal feline infectious peritonitis (FIP) in domestic cats 
(Vennema et al. 1998). A highly virulent variant of CCoV is known since 2005 (Buonavoglia 
et al. 2006). FCoV, CCoV and TGEV have an evolutionary history of common ancestors as 
well as several recombination events (Le Poder 2011), proving the ability of coronaviruses to 
cross species barriers repeatedly.  
Human and porcine alphacoronaviruses could be associated with common colds and 
infections of the respiratory tract. For HCoV-229E, TGEV and PEDV a correlation with 
gastroenteritis could be shown (Tyrrell et al. 1965; Bradburne et al. 1967; Garwes 1988; 
Hofmann et al. 1988).  
A rapidly increasing number of bat coronaviruses (Poon et al. 2005; Chu et al. 2006; Tang et 
al. 2006; Dominguez et al. 2007; Lau et al. 2007; Chu et al. 2008; Gloza-Rausch et al. 2008; 
Pfefferle et al. 2009; Drexler et al. 2010) is also allocated to this genus as unclassified 
alphacoronaviruses. These findings support the thesis that bats serve as genetic reservoir for 
alpha- and betacoronaviruses (Woo et al. 2012). 
1.1.1.2 Betacoronavirus 
The genus Betacoronavirus contains three human coronavirus species, human coronavirus 
OC43 (HCoV-OC43), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), 
human coronavirus HKU1 (HCoV-HKU1) and the novel human coronavirus EMC (HCoV-
EMC). HCoV-OC43 (McIntosh et al. 1967) was isolated in 1967 from throat swabs of patients 
with common cold. Until the SARS outbreak in 2003 (Drosten et al. 2003; Peiris et al. 2003; 
Rota et al. 2003) it was the only known human coronavirus in this group. With the discovery 
of SARS-CoV as the causative agent for the SARS epidemic the focus on coronaviruses led 
to the discovery of many new viruses including the HCoV-HKU1 (Woo et al. 2005), several 
novel bat (Tang et al. 2006; Woo et al. 2006; Woo et al. 2007; Drexler et al. 2010), bat 
SARS-like (Lau et al. 2005; Li et al. 2005; Yuan et al. 2010) and civet SARS-like coronavirus 
species (Guan et al. 2003; Wang et al. 2005). The betacoronaviruses HCoV-OC43 and 
HCoV-HKU1 together with the alphacoronaviruses HCoV-229E and HCoV-NL63 belong to 
the group of coronaviruses associated with respiratory tract infections (RTI) and common 
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colds in humans. HCoV-HKU1 was also associated with pneumonia (Lau et al. 2006) and in 
some cases with gastrointestinal disease (Vabret et al. 2006).  
The type species is represented by murine coronavirus (MHV) (Nelson 1957), the species 
betacoronavirus 1 contains bovine coronavirus (BCoV) (Stair et al. 1972), canine respiratory 
coronavirus (CRCoV) (Erles et al. 2003), equine coronavirus (ECoV) (Huang et al. 1983), 
HCoV-OC43 (McIntosh et al. 1967) and the porcine hemagglutinating encephalomyelitis 
virus (PHE-CoV) (Mengeling et al. 1972). HCoV-HKU1 (Woo et al. 2005), and SARS-related 
CoV represent single species, additionally several species containing exclusively bat 
coronaviruses were defined, namely the former coronavirus groups 2b (Drexler et al. 2010), 
and 2c (Tang et al. 2006), the Pipistrellus bat coronavirus HKU5 (Woo et al. 2006), the 
Rousettus bat coronavirus HKU9 (Woo et al. 2007) and the Tylonycteris bat coronavirus 
HKU4 (Woo et al. 2006) (see Figure 2). Several other bat, bovine and one human 
coronavirus species (Reusken et al. 2010; Watanabe et al. 2010) are subsumed as 
unclassified betacoronaviruses. 
The most prominent and best studied members of the betacoronaviruses are MHV and 
SARS-CoV. MHV causes bronchiolitis, infects the liver and brain of mice and is used as a 
model organism to study the pathogenesis of coronaviruses (Perlman et al. 1987). Infection 
of mice with MHV poses a challenge for unbiased research in specific pathogen free (SPF) 
facilities (Torrecilhas et al. 1999; Na et al. 2010). SARS-CoV is studied intensely since its 
sudden, rapid outbreak in early 2003 and due to the comparatively high mortality caused by 
SARS (Drosten et al. 2003; Guan et al. 2003; Rota et al. 2003). 
The novel human coronavirus MERS-CoV (Zaki et al. 2012) was discovered in 2012, its 
zoonotic potential and suspected potential of person-to-person transmission are currently 
under investigation (Kindler et al. 2013).   
1.1.1.3 Gammacoronavirus 
The genus Gammacoronavirus comprises mainly avian born coronaviruses, pooled in a 
species designated avian coronavirus. The infectious bronchitis virus (IBV) was the first 
avian coronavirus discovered, causing impaired egg production in adult and respiratory 
symptoms in young chickens (Cunningham 1970) and being the sole representative of 
Gammacoronavirus for several decades. The number of coronaviruses discovered in 
different bird species belonging to different orders increased rapidly over the past years. To 
date bulbul, duck, goose, munia, pheasant, pigeon, thrush and turkey coronaviruses are 
known (Gough et al. 1996; Jonassen et al. 2005; Liu et al. 2005; Gomaa et al. 2008; Woo et 
al. 2009). In view of the genetic diversity of alpha- and betacoronaviruses, the narrower 
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genetic range of gammacoronaviruses suggests that many undiscovered members of the 
genus may exist (Woo et al. 2009) (see Figure 2). 
The only mammalian-associated species in this genus is represented by the beluga whale 
coronavirus SW1 (Mihindukulasuriya et al. 2008). 
1.1.1.4 Deltacoronavirus 
In 2010 a new genus was proposed to and accepted by ICTV, named Deltacoronavirus. The 
genus comprises several new avian born coronaviruses, represented by bulbul coronavirus 
HKU11, thrush coronavirus HKU12 and munia coronavirus HKU13 (Woo et al. 2012). 
Interestingly also mammalian coronaviruses like the porcine coronavirus HKU15 are closely 
related to the avian coronaviruses within the genus Deltacoronavirus. These novel 
coronaviruses support the thesis of bat coronaviruses being the reservoir and ancestral 
lineage of alpha- and betacoronaviruses in contrast to avian coronaviruses being the gene 
source of gamma- and deltacoronaviruses (see Figure 3).  
 
 
Figure 3: A model of coronavirus evolution. CoVs in bats are the gene source of Alphacoronavirus and 
Betacoronavirus, and CoVs in birds are the gene source of Gammacoronavirus and Deltacoronavirus (Woo et al. 
2012). 
1.1.2 HCoV-NL63 epidemiology and pathogenesis 
The human coronavirus NL63 was isolated independently by two work groups in the 
Netherlands in 2004. Both isolates were obtained from young children, aged seven and eight 
months, suffering from respiratory tract infections (Fouchier et al. 2004; van der Hoek et al. 
2004). Although HCoV-NL63 was discovered recently, it has presumably been circulating in 
the human population worldwide for many decades. The oldest sample known to date was 
detected in a nasal wash specimen from 1981 (Talbot et al. 2009). 
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Several studies were carried out to determine the prevalence of HCoV-NL63 infections in 
respiratory samples of inpatients and outpatients of different ages. In the age cohort of 
children under five years the incidence of HCoV-NL63 ranged from 1.1 to 9.3%, depending 
on the type of study, location, period and population screened (Abdul-Rasool et al. 2010; 
Principi et al. 2010). As shown in a birth cohort study on 13 newborns, seroconversion 
against HCoV-NL63 occurs in young children, foremostly at an age below 3.5 years (Dijkman 
et al. 2008). HCoV-NL63 infection is also observed frequently in elderly and 
immunocompromised patients and in patients with underlying pulmonary conditions 
(Fouchier et al. 2004; Arden et al. 2005; Bastien et al. 2005; Bastien et al. 2005; Moes et al. 
2005). 
A variety of respiratory symptoms is connected to HCoV-NL63 infections. Mild symptoms in 
otherwise healthy children include common colds and upper respiratory tract infections 
(URTI) with fever, cough, rinorrhea and pharyngitis (Vabret et al. 2005). More severe 
symptoms like bronchiolitis (Arden et al. 2005; Bastien et al. 2005; Ebihara et al. 2005) and 
croup (Arden et al. 2005; Chiu et al. 2005; van der Hoek et al. 2005; Wu et al. 2008; van der 
Hoek et al. 2010) occur during lower respiratory tract infections (LTRI). In temperate climates 
HCoV-NL63 circulates mainly during the winter season along with influenza A virus, 
respiratory syncytial virus, parainfluenza virus, human metapneumovirus and other human 
coronaviruses. Double infections with other respiratory viruses are often present in HCoV-
NL63 positive patients (Chiu et al. 2005; Kaiser et al. 2005; van der Hoek et al. 2005; 
Lambert et al. 2007; Wu et al. 2008), making it sometimes difficult to correlate symptoms with 
one causative virus (Pyrc et al. 2006). 
1.1.3 Coronavirus replication and life cycle 
Coronavirus infections are initiated by binding of viral spikes to cellular receptors. 
Interestingly, even though HCoV-NL63 and SARS-CoV are only 46% identical on nucleotide 
level and 21% similar on amino acid level (van der Hoek et al. 2006), these viruses use the 
same receptor for cell entry, the membrane-bound angiotensin-converting enzyme 2 (ACE2) 
(Hofmann et al. 2005). However, the spike proteins of both viruses seem to bind to different 
domains of the receptor (Wu et al. 2009). The use of ACE2 by HCoV-NL63 is exceptional as 
almost all known alphacoronaviruses use the aminopeptidase N (CD13).  
Coronavirus´ cellular entry is mediated by the spike subunits and can facilitate entry in two 
ways. Most coronaviruses apply a receptor-mediated endocytosis followed by fusion of virus 
and host cell membranes in the acidic environment of an endosome to enter cells (Huang et 
al. 2006; Heald-Sargent et al. 2012). Alternatively coronaviruses facilitate a direct fusion of 
the virus envelope with the cellular plasma membrane mediated by proteases (Heald-
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Sargent et al. 2012). This way of entry was proven for SARS-CoV using transmembrane 
protease serine 2 (TMPRSS2) or human airway trypsin-like protease (Matsuyama et al. 
2010; Glowacka et al. 2011). 
The nucleocapsid is released into the cytoplasm and the genomic positive strand RNA 
serves as mRNA for the synthesis of the first viral proteins, namely the product of ORF 1a/b, 
the replicase polyprotein. Autocatalytic proteases cleave the nascent polyprotein and release 
up to 16 non-structural proteins (nsp, see Figure 4) (Ziebuhr et al. 2000; Snijder et al. 2003). 
 
Figure 4: The Coronavirus life cycle. The coronaviruses enter their target cells through membrane fusion or an 
endosomal pathway. The viral genome is released and translated into viral replicase polyproteins (pp) 1a and 
1ab, which are then autocatalytically cleaved into smaller products by viral proteases. Products of the ORF 1a/b 
form the replication complex, which synthesizes the full-length negative strand genome and also the subgenomic 
negative strand templates by discontinuous transcription. These negative strand RNAs serve as templates for the 
plus strand genome and plus strand mRNA synthesis. Viral nucleocapsids are assembled from genomic RNA and 
N protein in the cytoplasm, followed by budding into the lumen of the ERGIC (endoplasmic reticulum (ER)–Golgi 
intermediate compartment). Virions are then released from the cell via exocytosis (Stadler et al. 2003). 
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Recent data suggest that most, if not all of the encoded proteins, play a role in in vivo 
replication of the coronaviruses (Perlman et al. 2009). The RNA modifying enzymes form a 
replication complex that is associated with cytoplasmic membranes (Hagemeijer et al. 2010). 
In this replication complex a full-length negative strand copy of the genome is synthesized, 
which serves as template for the positive strand genomic RNA. Additionally the subset of 
shorter, subgenomic mRNAs is derived from discontinuous minus-strand synthesis. Their 
formation is facilitated by the leader and body transcription regulatory sequence (TRS) 
(Sawicki et al. 2007). All subgenomic mRNAs have a common 5’ end corresponding to the 
60-100 most proximal nucleotides at the 5’ end of the genome. During minus-strand 
synthesis, base pairing complementarity of leader and body TRS enable redirection of the 
nascent minus strand RNA and by this means the addition of the 5’ untranslated sequence to 
every subgenomic minus-strand RNA and the subgenomic mRNAs transcribed thereof 
((Pasternak et al. 2006) see Figure 5). 
 
 
Figure 5: Model-based on discontinuous extension of minus-strand RNA synthesis. Minus-strand RNA can 
be either continuous (producing the anti-genome) or discontinuous (yielding sg-length minus strands). The body 
TRSs in the genome act as attenuation signals for minus-strand RNA synthesis, after which the nascent minus 
strand, having an anti-body TRS at its 3‘ end, are redirected to the 5‘-proximal region of the template, guided by a 
base-pairing interaction with the leader TRS. Following the addition of the anti-leader (”L) to the nascent minus 
strands, the sg-length minus strands serve as templates for transcription. Modified from (Pasternak et al. 2006) 
 
Nucleocapsid and genomic RNA are assembled and transported to the membrane system 
where membrane, envelope and spike proteins are located. Viral particles are assembled 
and bud into the lumen of the ERGIC. The virions mature during their passage through the 
Golgi system and are released by endocytosis (see Figure 4) (Masters 2006; Acheson 2007). 
New publications prove coronavirus-induced membrane alterations, namely the formation of 
a reticulovesicular network (RVN), derived from endoplasmatic reticulum (ER) membranes. 
Viral RNA synthesis was detected in double-membrane vesicles (DMVs) which are part of 
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the RVN (Knoops et al. 2008; Perlman et al. 2009). Nevertheless an involvement of the 
ERGIC remains possible and the interaction of the viral replication/transcription complex 
(RTC) with cellular pathways needs further investigation (Knoops et al. 2010). 
1.1.4 Coronavirus genome organization 
The coronavirus genome consists of positive-sense single-stranded RNA, carrying a 5’ 
terminal cap and a 3’ polyadenylated poly(A) tail (Perlman et al. 2009). Depending on the 
virus species it codes for six to ten genes.  
All coronaviruses show a highly conserved order of genes, starting with the ORF 1a/b that 
covers two third of the whole genome and encodes the replicase complex, followed by the 
spike (S), the small envelope protein (E), the membrane protein (M) and the nucleocapsid 
protein (N) (see Figure 6).  
 
Figure 6: Genome organization of HCoV-NL63. Open reading frames (ORF) 1-6 and non-structural proteins 
(nsp) 1-16 with their putative functions. Function of nsps from SARS-CoV, see (Perlman et al. 2009). 
 
Some of the coronavirus species carry additional genes like the hemagglutinin esterase (HE) 
acquired by some Betacoronavirus species (Lissenberg et al. 2005; Zeng et al. 2008). In 
particular SARS-CoV has a multitude of accessory open reading frames encoding proteins 
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3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b. Most of those genes are groups-specific and dispensable 
for virus replication in vitro (McBride et al. 2012). A common accessory gene for most 
coronaviruses is ORF 3 (Tang et al. 2006). In case of HCoV-NL63 protein 3 is a glycosylated 
membrane protein that is incorporated into viral particles with yet unknown in vivo function  
(Muller et al. 2010). The role of some of the nsps (see Figure 6) and accessory proteins in 
coronavirus replication and life cycle is yet unknown. 
1.2 Reverse genetics 
A viral reverse genetics system is a tool to examine the role of specific genes and proteins in 
a whole virus context during the viral life cycle. The basic approach in reverse genetics is to 
alter the sequence of the gene of interest, create a genetically modified recombinant 
organism and compare the phenotype of the modified virus with that of the wild type 
(Almazan et al. 2000; Yount et al. 2000; Thiel et al. 2001; Gonzalez et al. 2002; Yount et al. 
2002; Yount et al. 2003; Coley et al. 2005; Thiel et al. 2005; Almazan et al. 2006; Pasternak 
et al. 2006; Zust et al. 2007; Donaldson et al. 2008; Pfefferle et al. 2009; Cervantes-Barragan 
et al. 2010; Ribes et al. 2010; Tischer et al. 2012). 
Using reverse genetics for plus strand RNA viruses requires the assembly of clones carrying 
the genome as complementary DNA (cDNA). Modifications are introduced in vitro on cDNA 
clone level. After transcription of RNA from the cDNA, the RNA is transfected into cells. The 
transfected cells produce modified virus particles, which can be further investigated (Semler 
et al. 1984; van der Werf et al. 1986; Rice et al. 1987). 
Reverse genetics systems generally have a high potential not only to examine gene 
functions, but also to clone chimeric viruses. By that virus-host interactions as well as 
recombination and host-switching events can be investigated. This can contribute greatly to a 
better understanding of sudden shifts in pathogenesis and host range as occurred prior to 
the SARS-CoV outbreak in 2002/2003. Further promising applications lie in the development 
of vaccines using recombinant coronaviruses as vehicles for antigen delivery. Similar 
approaches were already successfully realized with TGEV and MHV (Zust et al. 2007; 
Cervantes-Barragan et al. 2010; Ribes et al. 2010). 
As coronaviruses carry the largest single-strand RNA genome known to date, various pitfalls 
complicate the assembly of 27-32 kb in one cDNA clone (Almazan et al. 2000; Yount et al. 
2000; Thiel et al. 2001). Genome size is the major challenge; additionally parts of the 
coronavirus genome appear to have toxic effects on E. coli leading to cloning and stability 
difficulties on cDNA clone level (Almazan et al. 2000; Yount et al. 2000; Thiel et al. 2001; 
Tischer et al. 2012).  
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A BAC-based cloning strategy was previously established  to generate an infectious full-
length SARS-CoV cDNA clone (Pfefferle et al. 2009). The full-length SARS-CoV cDNA 
genome was cloned into a BAC backbone, including a T7 polymerase promoter at the 5’ end 
of the genome and a poly (A) tail at the 3’ end. Linearized cDNA served as template for T7 
driven in vitro transcription (IVT). The capped, polyadenylated infectious RNA was 
electroporated into mammalian cells and recombinant virus could be rescued. This approach 
combines the advantage of mutagenesis-friendly plasmid-based handling of the virus cDNA 
genome as well as the transfection of capped infectious RNA into the cytosol of the host cell, 
mimicking a natural virus infection (see Figure 7). 
 
 
Figure 7: BAC-based reverse genetics system of SARS-CoV. Schematic illustration of SARS-CoV infectious 
cDNA clone. The virus full-length cDNA genome is integrated into a pBelo BAC backbone, a T7 promoter and a 
poly (A) tail are added at the 5’ and 3’ end, respectively. Linearized pBelo BAC serves as template for capped T7 
driven in vitro transcription. RNA is electroporated into susceptible mammalian cells and recombinant virus is 
rescued. 
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1.3 Aim of the thesis 
The aim of the thesis was the characterization and construction of a novel reverse genetics 
system for HCoV-NL63 strain Amsterdam 1 that is based on a BAC backbone, that uses 
phage promoter-driven in vitro RNA synthesis from a cDNA full-length clone, and that 
involves efficient transfection of infectious RNA into the cytosol of susceptible mammalian 
cells.  
For this purpose sequence correctness of the parental HCoV-NL63 strain Amsterdam 1 had 
to be verified. Additionally, it was desirable to identify susceptible cell lines that support 
replication of HCoV-NL63 to higher titers and to develop a novel HCoV-NL63 plaque assay, 
serving as useful tool in the establishment of a reverse genetics system.  
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2 Material and Methods 
2.1 Material 
2.1.1 Equipment 
Equipment Type Source 
Autoclave V 120 Systec, Wettenberg 
Balance SPO 61  
SBA 32 
Scaltec, Göttingen 
Scaltec, Göttingen 
blue-light transilluminator Flu-O-Blu Biozym, Hess. Oldendorf 
Centrifuges Biofuge Pico 
5804R 
Sorvall Evolution RC 
Heraeus, Hanau 
Eppendorf, Hamburg 
Thermo Fischer Scientific, 
Waltham, USA 
Electroporation System Gene Pulser Xcell Bio-Rad Laboratories, Munich 
Freezer -20°C Liebherr premium 
-70°C 
Liquid nitrogen LS 750 
Liebherr, Biberach a. d. Riß 
 
Taylor-Wharton, Mildstedt 
Gel documentation CCTV camera 
Video graphic printer UP-
895 CE 
Monitor 
Monacor international, Bremen 
Sony, Berlin 
 
Sony, Berlin 
Gel electrophoresis Mini-Sub Cell GT 
PerfectBlue Gelsystem 
Mini M 
Horizon 11.14 
Bio-Rad Laboratories, Munich 
PEQLAB, Erlangen 
 
(Gibco BRL Life Technologies), 
Invitrogen, Karsruhe 
Heating block Thermomixer comfort Eppendorf, Hamburg 
Laminar flow Gelaire BSB-4A ICN Biochemicals, Eschwege 
Incubators INB 500 
CB 150 
Memmert, Schwabach 
Binder, Tuttlingen 
Magnetic plate Agencourt SPRIPlate 
Super Magnet Plate 
Beckman Coulter, Krefeld 
Magnetic stirrer REO basic IKAMAG IKA-Labortechnik, Staufen 
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Microscopes Leitz Diavert 
Leica DM IL + DFC 320 
Leitz, Wetzlar 
Leica Microsystems, Wetzlar 
Column loader for 
MultiScreen plates 
Multiscreen Column 
Loader,45 µl 
Millipore, Munich 
Cell counting chamber Neubauer Roth, Karlsruhe 
Photometer BioPhotometer Eppendorf, Hamburg 
Pipette assistance Accu-jet® pro Brand, Wertheim 
Pipettes 0,5-10 µl, 2-20 µl, 20-
200 µl, 100-1000 µl 
Eppendorf, Hamburg 
Power supplies E865 
E425 
E132 
Consort, Turnhout, Belgium 
Real-Time Cycler LightCycler 1.5 
LightCycler 480 
ABI Prism 7000 
Roche Diagnostics, Mannheim 
Roche Diagnostics, Mannheim 
Applied Biosystems, Carlsbad, 
USA 
Refrigerator Liebherr Premium Liebherr, Biberach a. d. Riß 
Rotating incubator GFL-3033 GFL, Burgwedel 
Sequencer ABI PRISM® 3100 
Genetic Analyzer 
Applied Biosystems, Carlsbad, 
USA 
Thermocycler Mastercycler ep 
Primus 25 advanced 
Eppendorf, Hamburg 
PEQLAB, Erlangen 
UV transilluminator Bioview UXDT-40SL-15E Biostep, Jahnsdorf 
Vertical shaker Mini Rocker MR-1 PEQLAB, Erlangen 
Vortexer Vortex VF2 IKA-Labortechnik, Staufen 
Water bath 1002 GFL, Burgwedel 
2.1.2 Chemicals 
Item Source 
5-bromo-4-chloro-3-indolyl-beta- 
D-galactopyranoside (X-Gal) 
Roth, Karlsruhe 
Acetone Roth, Karlsruhe 
Agarose Broad Range Roth, Karlsruhe 
Agarose GTQ Roth, Karlsruhe 
Albumin from bovine serum Roche Diagnostics, Mannheim 
Ampicillin Sigma-Aldrich, Munich 
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Ampuwa® (sterile water) Fresenius Kabi, Bad Homburg 
Bovine Serum Albumin (BSA) New England Biolabs, Frankfurt am Main 
Bromophenol blue (Tetrabromophenol 
sulfonephthalein) 
Sigma-Aldrich, Munich 
Calcium chloride (CaCl2) Roth, Karlsruhe 
Carbenicillin Roth, Karlsruhe 
Chloramphenicol Sigma-Aldrich, Munich 
Hydrochloric acid (HCl) Roth, Karlsruhe 
Chloroform Roth, Karlsruhe 
Crystal violet Sigma-Aldrich, Munich 
DakoCytomation DakoCytomation, Glostrup, Denmark 
Deionized water (Milli-Q) Millipore, BNI 
Diethylpyrocarbonate (DEPC) Roth, Karlsruhe 
Dimethyl sulfoxide (DMSO) Roth, Karlsruhe 
Disodium hydrogen phosphate Merck, Darmstadt 
dNTP set (dATP, dTTP, dGTP, dCTP) Qiagen, Hilden 
Ethanol (> 96%) Roth, Karlsruhe 
Ethidium bromide (10 mg/ml) Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) Serva, Heidelberg 
Formaldehyde (37%) Roth, Karlsruhe 
FuGENE ® HD transfection reagent Roche Diagnostics, Mannheim 
GelStar® Nucleic Acid Gel Stain Lonza, Rockland, USA 
Glycerol Roth, Karlsruhe 
Hi-Di™ Formamide Applied Biosystems, Carlsbad, USA 
Isopropyl alcohol Roth, Karlsruhe 
Isopropyl β-D-1- thiogalactopyranoside 
(IPTG) 
Roth, Karlsruhe 
Kanamycin Sigma-Aldrich, Munich 
LiChrosolv® (HPLC water) Merck, Darmstadt 
Magnesium chloride Sigma-Aldrich, Munich 
Opti-MEM® Invitrogen, Karlsruhe 
Phenol (Rotiphenol®) Roth, Karlsruhe 
POP-6™ Polymer for the 310 Genetic 
Analyzer 
Applied Biosystems. Carlsbad, USA 
Potassium chloride (KCl) Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) Merck, Darmstadt 
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RNAlater Qiagen, Hilden 
Roti® Block Roth, Karlsruhe 
Saccharose Roth, Karlsruhe 
Sephadex G-50 Superfine GE Healthcare, Munich 
Sodium carbonate anhydrous Roth, Karlsruhe 
Sodium chloride (NaCl) Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS) Serva, Heidelberg 
Sodium hydrogen phosphate (Na2HPO4) Merck, Darmstadt 
Sodium hydroxide (NaOH) Roth, Karlsruhe 
Sucrose Sigma-Aldrich, Munich 
Tris hydroxymethyl aminomethane (Tris) Roth, Karlsruhe 
Triton X-100 Sigma-Aldrich, Munich 
Trizol® Invitrogen, Karlsruhe 
Trypsin PAA, Cölbe 
Tween® 20 Sigma-Aldrich, Munich 
Xylene cyanol FF Sigma-Aldrich, Munich 
2.1.3 Consumables 
Item Source 
96 well septa Applied Biosystems, Carlsbad, USA 
Cell culture flasks with filter cap (25 cm², 75 
cm², 175 cm²) 
Sarstedt, Nümbrecht 
Cell culture plates (6-well, 24-well) Sarstedt, Nümbrecht 
Cell scraper TPP, Trasadingen, Switzerland 
Cover glass slides (12 mm, round) Roth, Karlsruhe 
Cryotubes Sarstedt, Nümbrecht 
Cuvettes (Eppendorf UVette®) Eppendorf, Hamburg 
Electroporation cuvettes (1 mm, 2 mm gap) Biozym, Hess. Oldendorf 
LightCycler® Capillaries, 20 µl Roche Diagnostics, Mannheim 
MultiScreenHTS-HV Plates Millipore, Schwalbach 
Parafilm  Alcan Packaging, Neenah, USA 
PCR reaction tubes 0,2 ml Sarstedt, Nümbrecht 
Petri dishes Sarstedt, Nümbrecht 
Pipette Tips (10 µl, 20 µl, 200 µl, 1000 µl) Sarstedt, Nümbrecht 
Reaction tubes (1.5 ml, 2 ml) Sarstedt, Nümbrecht 
Reaction tubes, safe lock (1.5 ml, 2 ml) Eppendorf, Hamburg 
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Reaction tubes (15 ml, 50 ml) Sarstedt, Nümbrecht 
Scalpel B. Braun Aesculap, Tuttlingen 
Seropipettes (5 ml, 10 ml, 25 ml) Sarstedt, Nümbrecht 
Sterile filtration unit (Stericup and Steritop)  Millipore, Schwalbach 
Sterile filter (0.22 µm) Sarstedt, Nümbrecht 
2.1.4 Buffer/Solutions 
Name Composition Source 
6x Loading Dye 40% Sucrose 
0.15% Bromophenol blue 
0.15% Xylene cyanol FF 
In deionized water 
- 
Crystal violet stock solution 20 g/l crystal violet 
100 ml/l Formaldehyde (37%) 
200 ml/l Ethanol (>96%) 
In deionized water 
- 
Crystal violet working 
solution 
100 ml/l Crystal violet stock 
solution 
100 ml/l Formaldehyde (37%) 
In deionized water 
- 
Diethylpyrocarbonate 
(DEPC) water 
0.1% DEPC (v/v)  
In deionized water 
- 
Phosphate buffered saline 
(PBS) 10x buffer 
1.37 M NaCl  
27 mM KCl  
100 mM Na2HPO4  
20 mM KH2PO4  
pH 7.4 
In deionized water 
AccuGene; BioWhittaker, 
Rockland, USA 
PBS 1x buffer 100 ml/l 10x PBS 
In deionized water 
- 
Tris-acetate-EDTA (TAE) 
50x buffer 
2 M Tris-acetate 
0.05 M EDTA 
1 M glacial acetic acid 
In deionized water 
pH 7.8 
- 
TAE 1x buffer 20 ml/l 50x TAE - 
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In deionized water 
PBST 0.05% Tween 20 (v/v) 
In 1x PBS 
 
0,1% Triton X-100 0.1% Triton X-100 (v/v) 
In 1x PBS 
 
0,5% Triton X-100 0.5% Triton X-100 (v/v) 
In 1x PBS 
 
Blocking solution 10% FCS (v/v) 
In 1x PBS 
 
4% Formaldehyde 4% Formaldehyde (v/v) 
In 1x PBS 
 
2.1.5 E. coli culture 
2.1.5.1 Media  
LB (lysogenic broth) 20 g/l in deionized water Roth, Karlsruhe 
LB Agar 35 g/l in deionized water Roth, Karlsruhe 
S.O.C. Medium  Invitrogen, Karlsruhe 
Recovery Medium  Lucigen, Middleton, USA 
2.1.5.2 Antibiotic Stock solutions 
Carbenicillin 50 mg/ml in 50% Ethanol Roth, Karlsruhe 
Chloramphenicol 34 mg/ml in > 96% Ethanol  Sigma-Aldrich, Munich 
Kanamycin 50 mg/ml in 0.9% sodium 
chloride 
Sigma-Aldrich, Munich 
2.1.5.3 Bacteria 
Name Genotype Source 
E. cloni 10G (supreme, elite) 
Electrocompetent cells 
F- mcrA Δ(mrr-hsdRMS-mcrBC) 
endA1 recA1 Φ80dlacZΔM15 
ΔlacX74 araD139 
Δ(ara,leu)7697 galU galK rpsL 
nupG λ- tonA 
Lucigen, Middleton, USA 
One Shot® Stbl3™ 
chemically competent cells 
F– mcrB mrr hsdS20(rB–, mB–) 
recA13 supE44 ara-14 galK2 
lacY1 proA2 rpsL20(StrR) xyl-5 
– leu mtl-1 
Invitrogen, Karlsruhe 
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One Shot® TOP10 
chemically competent cells 
F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara leu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen, Karlsruhe 
2.1.6 Cell culture 
2.1.6.1 Media and overlays 
Name Composition Source 
DMEM (Dulbecco’s Modified 
Eagles Medium) high 
glucose (4,5 g/L) 
100 ml/l Fetal Calf Serum (FCS) 
10 ml/l 100x 
Penicillin/Streptomycin 
(Pen/Strep) 
10 ml/l 100x MEM nonessential 
amino acids (MEM NEAA) 
10 ml/l 100x L-glutamine 
10 ml/l 100x Sodium pyruvate 
In DMEM 
all PAA, Cölbe 
OptiPro™ SFM (serum-free 
medium) 
10 ml/l 100x L-glutamine 
10 ml/l 100x Pen/Strep 
in OptiPro™ SFM 
PAA, Cölbe 
PAA, Cölbe 
Invitrogen, Karlsruhe 
2x DMEM 13.54 g/l INSTAMED DMEM dry 
powder 
200 ml/l FCS 
20 ml/l 100x Pen/Strep 
20 ml/l 100x MEM NEAA 
20 ml/l 100x L-glutamine 
20 ml/l 100x Sodium pyruvate 
In DMEM 
Biochrom, Berlin 
 
PAA, Cölbe 
PAA, Cölbe 
PAA, Cölbe 
PAA, Cölbe 
PAA, Cölbe 
PAA, Cölbe 
Avicel® RC581 2.4% Avicel® RC581 (w/v) 
In deionized water 
FCM BioPolymer, 
Brussels, Belgium 
Biozym Plaque Agarose 2% Plaque Agarose (w/v) 
In deionized water 
Biozym, Hess. Oldendorf 
Carboxymethyl-cellulose 
sodium salt (CMC) 
1.6% CMC (w/v) 
In DMEM 
BDH, Poole, UK 
PAA, Cölbe 
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Cryopreservation medium 
 
10% DMSO (v/v) 
40% DMEM (v/v) 
50% FCS (v/v) 
Roth; Karlsruhe 
PAA, Cölbe 
PAA, Cölbe 
2.1.6.2 Cells 
293lp human embryonic kidney (ATCC CRL-1573), 
BHK-J Baby hamster kidney (cell culture collection of the BNI) 
BSR-T7 BHK cell line constitutively expressing a T7 RNA polymerase, (BNI, 
originating from K.-K. Conzelmann, Ludwig-Maximilians-University Munich) 
CaCo-2 human colon carcinoma (ATCC HTB-37) 
Calu1 human lung carcinoma (ICLC HTL95002) 
Calu6 human lung carcinoma (ICLC HTL97003) 
FeA feline embryonic fibroblast (kindly provided by Dr. Marcel Asper, NewLab 
Inc., Cologne) 
LLC-MK2 rhesus monkey kidney (ATTC CCL-7, kindly provided by Lia van der Hoek, 
Academic Medical Center Amsterdam, The Netherlands). 
PK 13 porcine kidney (cell culture collection of the Bernhard-Nocht-Institute (BNI) 
POEK porcine fetal kidney (cell culture collection of the Robert Koch-Institute (RKI), 
Berlin, Germany) 
PS porcine kidney cells (RKI) 
RD human rhabdomyosarcoma cells (RKI) 
Vero E6 rhesus monkey kidney (ATCC CRL-1586) 
Vero FM rhesus monkey kidney (ATCC CCL-81) 
2.1.6.3 Virus 
Name Strain (Accession No.) Source 
HCoV-NL63 Amsterdam 1, 8th passage 
(NC_00581) 
Dr. Lia van der Hoek, Academic Medical 
Center (AMC) Amsterdam, The Netherlands 
2.1.7 Kits 
Name Source 
310 Running Buffer 10x Applied Biosystems, Carlsbad, USA 
Agencourt® AMPure® Beckman Coulter, Krefeld 
BigDye® Terminator v3.1 Cycle Sequencing 
Kit 
Applied Biosystems, Carlsbad, USA 
CloneSmart® Blunt LC Cloning Kit Lucigen, Middleton, USA 
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GeneJET™ Plasmid Miniprep Kit 
 
Thermo Fisher Scientific (Fermentas), St. 
Leon Roth 
GeneRacer™ Kit Invitrogen, Karlsruhe 
mMessage mMachine® Kit T7 and SP6 Ambion (Applied Biosystems), Darmstadt 
NucleoBond Xtra Midi Macherey & Nagel, Düren 
Opti-4CN™ Substrate Kit Bio-Rad Laboratories, Munich 
Phusion™ Site-Directed Mutagenesis Kit NEB (Finnzymes), Frankfurt am Main 
QIAamp Viral RNA Mini Kit Qiagen, Hilden 
QIAEX II Gel Extraction Kit Qiagen, Hilden 
QIAGEN OneStep RT-PCR Kit Qiagen, Hilden 
QuickChange® II XL Site-Directed 
Mutagenesis Kit 
Agilent Technologies (Stratagene), Böblingen 
SuperScript® III One-Step RT-PCR System 
with Platinum® Taq DNA Polymerase 
Invitrogen, Karlsruhe 
SuperScript™ One-Step RT-PCR with 
Platinum® Taq 
Invitrogen, Karlsruhe 
TOPO TA Cloning®  Kit for Sequencing Invitrogen, Karlsruhe 
2.1.8 Enzymes 
Name Source 
Herculase® II Fusion DNA Polymerase Agilent Technologies (Stratagene), 
Böblingen 
Phusion® High-Fidelity DNA Polymerase NEB (Finnzymes), Frankfurt am Main 
Platinum® Taq DNA Polymerase Invitrogen, Karlsruhe 
RNase H Invitrogen, Karlsruhe 
RNaseOUT™ Recombinant Ribonuclease Inhibitor Invitrogen, Karlsruhe 
SuperScript III® Reverse Transcriptase Invitrogen, Karlsruhe 
T4 DNA Ligase (5 U/µl) Roche Diagnostics, Mannheim 
2.1.9 Restriction Enzymes 
Name Source 
AatII NEB, Frankfurt am Main 
AatII Roche Diagnostics, Mannheim 
AatII Fast Digest Thermo Fisher Scientific (Fermentas), St. Leon Roth 
BamHI NEB, Frankfurt am Main 
BamHI Fast Digest Thermo Fisher Scientific (Fermentas), St. Leon Roth 
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BsaHI NEB, Frankfurt am Main 
BsrGI NEB, Frankfurt am Main 
EcoRI NEB, Frankfurt am Main 
EcoRI Fast Digest Thermo Fisher Scientific (Fermentas), St. Leon Roth 
FauI NEB, Frankfurt am Main 
KasI NEB, Frankfurt am Main 
MluI NEB, Frankfurt am Main 
NheI NEB, Frankfurt am Main 
NheI Fast Digest Thermo Fisher Scientific (Fermentas), St. Leon Roth 
NotI NEB, Frankfurt am Main 
NotI Fast Digest Thermo Fisher Scientific (Fermentas), St. Leon Roth 
PacI NEB, Frankfurt am Main 
PspOMI NEB, Frankfurt am Main 
SphI NEB, Frankfurt am Main 
2.1.10 Antibodies 
2.1.10.1 Primary antibodies 
Name Source 
Human Anti HCoV-NL63 Serum, BNI 
Rabbit Anti M (HCoV-NL63) (Muller 2007) 
Rabbit Anti N (HCoV-NL63) (Muller 2007) 
2.1.10.2 Secondary antibodies 
Name Source 
Donkey Anti-Rabbit IgG H & L Chain 
Specific Cy3 Conjugate 
Dianova, Hamburg 
Goat Anti-Human IgG H & L Chain Specific 
Peroxidase Conjugate 
Merck (Calbiochem), Darmstadt 
Goat Anti-Human IgG, H & L Chain Specific 
Fluorescein Conjugate  
Merck (Calbiochem), Darmstadt 
2.1.11 Molecular Weight Markers 
Name Source 
GeneRuler™ 100bp Plus DNA Ladder 
(fragment sizes [bp]: 100, 200, 300, 400, 
500, 600, 700, 800, 900, 1000, 1200, 1500, 
Thermo Fisher Scientific (Fermentas), St. 
Leon Roth 
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2000, 3000) 
GeneRuler™ 1kb DNA Ladder (fragment 
sizes [bp]: 250, 500, 750, 1000, 1500, 2000, 
2500, 3000, 3500, 4000, 5000, 6000, 8000, 
10000) 
Thermo Fisher Scientific (Fermentas), St. 
Leon Roth 
High Molecular Weight DNA Markers 
(fragment sizes [bp]: 8271, 8612, 10086, 
12220, 15004, 17057, 19399, 22621, 24776, 
29942, 33498, 38416, 48502) 
Invitrogen, Karlsruhe 
Supercoiled DNA Ladder, 2-10kb (band 
sizes [kb]: 2, 3, 4, 5, 6, 7, 8, 9, 10) 
Promega, Mannheim 
Supercoiled DNA Marker Set (band sizes 
[kb]: 8, 13, 18, 23, 28) 
Epicentre, Madison, USA 
2.1.12 Plasmids and BACs 
Name Map Source 
pCR®2.1  
 
www.invitrogen.com 
 
Invitrogen, 
Karlsruhe 
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pUC19 
 
www.invitrogen.com 
 
 
 
Invitrogen, 
Karlsruhe 
pBeloBAC11  
 
 
www.neb.com  
 
NEB 
(Finnzymes), 
Frankfurt am 
Main 
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pSMART® 
LCKan 
 
www.lucigen.com 
 
Lucigen, 
Middleton, 
USA 
 
2.1.13 Primer 
2.1.13.1 NL63 forward primers 
Names of primers correspond approximately to the 5’ nucleotide position of HCoV-NL63 
GenBank Accession number NC_005831. 
Name Sequence 
398F GTAGCCGTTCGCGCTTATAG 
1154F CTGGTAATGTCGTTCCTGGTG 
1928F CTGTTATTGAACTTGCCACTG 
2670F CACTGCTGGTGTTTGCATCA 
3100F GAAGATGATGTTGTTACCAGTCT 
3370F GGTGAGTGTTGTATTTGTCA 
4500F GCTTTGTTTAGTTGTGACAT 
B fw TCTGTAGCTCCAGAAGTTGACTG 
5730F GACGTGTTGTTATTACCAATGT 
6660F TAGCTACATTTATTGTCTGCA 
7010F TCGTCTTTATAGTGGTGACACT 
7430F TGTCCGTTTATGACATTGCT 
8290F CTAGAGGTTTTGGCTTACGTACT 
9091F GACATGTTATATTCTCCACCTAC 
10004F CACTAGCTGAAGTTGTGAAGC 
10458F GTGTTCTCTTATAGCAGTTGC 
10840F CTTGGTATTGGTGGTGACCG 
11566F GGTTCTGTTCATTATGCTGGAG 
12300F GTATGGATGGTTACTGTAAGT 
13105F GCTTACCTAATATGGGTGTTCC 
14040F CTCCCTACTATGACACAGCTG 
14467F GTGGTACGACTTCTGGTGAC 
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15264F ACTGTACTTCGTTGTGGTGA 
15977F AACCAAGAGAAGTATTCTAGC 
16510F CTCAACGTATGTGTGCTATAGG 
17102F GTCGTTGTCAGATCAGTTTAAGAC 
18832F GGGATTATGAAGCTGAAAGACC 
E fw ATGGATTTGTTGTTGGACGACT 
20185F GCACGTCTGTTAATACATCCTC 
20836F TGCTTCTAGTTCTTTTGACTG 
21637F TGTTGCTAGAACTGGCCAGT 
22246F GCTTGAAGCCACCTGGCATTAC 
23001F TGCTAACTTTCGATAGCAATGCT 
23751F GTTCGTGGTTCAAGACGCTTAGCAC 
24465F CTACAGGTTGTTGTGGTTGTTGC 
24498F CTTCATCAATGCGAGGCTGTTG 
25873F GTGATGGCTGCACCTACAGG 
26519F CGTAATCAGAAACCTTTGGAACC 
26999F GCTGAATTGATTCCTAATCAG 
2.1.13.2 NL63 reverse primers 
Names of primers correspond approximately to the 5’ nucleotide position of HCoV-NL63 
GenBank Accession number NC_005831. 
Name Sequence 
490R ATCATCATCATTAATACCGGTTACAC 
7520R AGTATTAAAGTCCTTGACAC 
11531R CTCCAGCATAATGAACAGAACC 
C rev CTATAACAATTATCATACAGACGTC 
14629R CATCAATGAATGACTCTTCAACAC 
18086R ACAGTACCATTTGGCATCAG 
18964R TACGAACCCTGAATACTATTG 
S22016R ACCATTAAGAGATATATTAACCTG 
22304R CTCACGAATACCAGAGACAGG 
25644R AGACAAAGCTAGAACAAGTGGC 
26096R CTCCTGAGAGGCAACACCAG 
2.1.13.3 Vector primers 
Name Sequence 
pBelo  
pBelo790F CATTAAGCATTCTGCCGACATG 
pBelo 1050R GCAAGATGTGGCGTGTTACGGTGA 
pBelo1290R CCTATAACCAGACCGTTCAGCTGGA 
pBeSCfwd GCCCTTAAACGCCTGGTTGCTAC 
pBeSCrev CGACAGGTGCTGAAAGCGAGC 
pBeSCrev_1 CTTTCCGGTGATCCGACAGG 
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pBeSCrev_2 GAATGAACAATGGAAGTCCGAGC 
pBELO Seq1 CCAGGGCTTCCCGGTATC 
pBELO Seq2 GAACAACCTAATGAACACAGAACC 
pBELO Seq3 GGAAGCCAGTAAGGATATACG 
pBELO Seq4 GCAGTTTGTCACAGTTGATTTCC 
pBELO Seq5 ATTGCGACGTGCTGAAGACG 
pBELO Seq6 GAAGTTGGTAAAGGTCAGATCC 
pBELO Seq7 GTATCAACACCGCCAAATTGC 
pBELO Seq8 CCCACTGTTCCACTTGTATCG 
pBELO Seq9 CCCGTATTCAGTGTCGCTG 
pSMART  
SL1 CAGTCCAGTTACGCTGGAGTC 
SR2 GGTCAGGTATGATTTAAATGGTCAGT 
pCR 2.1  
M13 reverse CAGGAAACAGCTATGAC 
M13 forward GTAAAACGACGGCCAG 
GeneRacer Kit  
GeneRacer™ 5′ Primer CGACTGGAGCACGAGGACACTGA 
GeneRacer™ 5′ Nested Primer GGACACTGACATGGACTGAAGGAGTA 
2.1.13.4 Construction primers 
Names of primers correspond approximately to the 5’ nucleotide position of HCoV-NL63 
GenBank Accession number NC_005831. 
Fragment A0  
NL63T7fwd +pspom Mlu atgctGGGCCCACGCGTtaatacgactcactatagcttaaagaatttttctatct 
490R_lang_AatII cagatgctgGACGTCatcatcatcattaataccggttacac 
Fragment A  
NL 350 F* gccattccttctgtagccgt 
NL4000R_AatII* tcatgcGACGTCtcaccagcttctatttctacactatg 
Fragment B1  
NL3716F* gttggttgtttgttttggattatg 
NL3716FplusMluI atgctACGCGTgttggttgtttgttttggattatg 
NL7520R_2+AatII* ttatgcGACGTCaagagtattaaagtccttgacaccc 
Fragment B2  
NL7430FplusMluI atgctACGCGTtgtccgtttatgacattgct 
NL 12460 R +Aat tgatgcGACGTCggttctagtcgagctgcact 
Fragment C  
S12300plusMluI atgctACGCGTgtatggatggttactgtaagt 
NL 14629 R catcaatgaatgactcttcaacac 
Fragment D  
NL 14507 F ACATTAACAGGTTGCTTAGTGTCC 
NL 21824 R plusNotI tcatgcGCGGCCGCctgcaagtgctcacactgc 
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Fragment E 
S 21637+Aat agaatgctgGACGTCTGTTGCTAGAACTGGCCAGT 
NL 25873 RplusNotI tcatgcGCGGCCGCCCTGTAGGTGCAGCCATCAC 
Fragment F  
NL 25644 F +Aat agaatgctgGACGTCGCCACTTGTTCTAGCTTTGTCT 
NL27553R+20t+NotI atgctgaGCGGCCGCttttttttttttttttttttgtgtatccatatcaaaaacaatatcattaac 
SP6 forward  
NL_SP6_F_Mlu ggccACGCGTatttaggtgacactataggcttaaagaatttttctatctatag 
* = 5’end phosphate; bold: restriction sites. 
2.1.13.5 RT Real-Time PCR primers 
63RF2 CTTCTGGTGACGCTAGTACAGCTTAT 
63RP FAM – CAGGTTGCTTAGTGTCCCATCAGATTCAT - TAMRA 
63RR2 AGACGTCGTTGTAGATCCCTAACAT 
2.1.13.6 Mutagenesis primers 
Subclone AF  
ORF1_delAar_fw2 GTTCCTGGTAATGTCGTTCCTGGTG 
ORF1_delAar_rev2 AACACAAAGTTTCTTAGCAGGCGTGC 
ORF1a1b_delNhe_fw TTTGCTGCCAGCACTGGTGTTATTG 
ORF1a1b_delNhe_rev TTTAACATCTTCTGTAACAGAAGCACC 
ORF6delNhe_fw CTAATAACTCATCTCGTGCCAGCAGTC 
ORF6delNhe_rev AGCGATCCTCAAACTCAACAACAGAG 
NL63-pB-NLA3-mut494F GTTGCAAGTGATTCGGAAATTTCAGG 
NL63-pB-NLA3-mut494R2 AGCAAGTGTCACTTGATTGTAAAACATGG 
Subclone C  
NL63-pB-C-mut2002F GACAATACCATCAAAAACATCTTAAATCCATTGC 
NL63-pB-C-mut2002R2 GCAATGGATTTAAGATGTTTTTGATGGTATTGTC 
Subclone D  
D2936corFw GCTTGCAATGTAAACCGTTTTAATGTTG 
D2936corRev ATGTGCAGTGTCAGAAGTTTGTGCATAG 
Subclone E  
pB_E_mut1562F_2 CAGACCAAGTAGCTGTTTATCAACAAAGC 
pB_E_mut1562R_2 GTTGGTTACATGGTGTCACAATAAAAATGTTAC 
pB_E_mut2503F_2 TACATACTGTTACTATTGCACTTAATAAGATTCAG 
pB_E_mut2503R_2 TAGCCTCTGCAGTTTGTGTAATAGCATC 
Deletion KasI subclone ADEF  
KasI_del_lang tgacccgcTTGGCGGCGTGTTAAAACTTTTTGG 
ADRP mutant subclone NLA3  
nsp3_NmutA_F GAGGCGGTGTTGCACGTGCTATTGATATTTTG 
nsp3_NmutA_R CATGCAAGAGATTTTCAGCAGCAGCATTGACAAC 
Bold: introduced mutations. 
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2.2 Methods 
2.2.1  Molecular biology methods 
Working with nucleic acids in general and with RNA in particular requires some precaution. 
To keep the risk of potential contamination with other nucleic acids as well as unspecific 
enzyme activities (RNase, DNase) low, plastic material was autoclaved (120°C and 1 bar 
pressure) and equipment like pipettes were decontaminated frequently. Additionally, only 
commercially available molecular grade water and guaranteed sterile and nuclease-free filter 
pipette tips were used for handling of RNA. If possible, commercially available kits and 
reagents were used to guarantee working with low contamination risk. In-house produced 
buffers and solutions for RNA handling were prepared with DEPC treated water. 
2.2.1.1 RNA extraction 
Viral RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) according to the 
manufacturers’ instructions. Elution was carried out with 60 µl of pre-warmed (80°C) elution 
buffer. Total RNA from cells was extracted using Trizol Reagent (Invitrogen) according to the 
manufacturers’ instructions. Additionally the RNA was routinely diluted 1:10 in sterile 
deionized water for downstream applications. Extracted RNA and dilutions thereof were 
stored at -20°C for short term and -80°C for long term. 
2.2.1.2 Isolation of plasmid DNA 
Bacteria were cultured in LB-broth (High copy plasmids only) or on LB-agarose plates (High 
copy plasmids and BAC) containing the appropriate antibiotic and harvested by 
centrifugation or scraping. Small scale isolation of high copy plasmids and BACs was done 
using the GeneJET™ Plasmid Miniprep Kit (Fermentas) according to the manufacturers’ 
instructions. Mid-scale isolation of high copy plasmids and BACs was done using the 
NucleoBond Xtra Midi Kit (Macherey & Nagel) according to the manufacturers’ instructions. 
Plasmid DNA was stored at -20°C or at -70°C for long term. 
2.2.1.3 Purification of PCR products 
Purification of PCR products was routinely done using Agencourt Ampure (Beckman 
Coulter). Prior to use the Ampure solution was mixed vigorously for 30 seconds using a 
Vortex. The 1.8 volumes of Ampure were added to one volume of a PCR reaction. Solutions 
were mixed well by pipetting up and down and incubated at room temperature. This step 
facilitates the binding of DNA to the Ampure beads. After 10 minutes the tube was 
transferred to a magnetic plate and incubated further 10 minutes to separate the beads from 
the supernatant. The supernatant was removed by pipetting and the beads were washed 
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twice with 200 µl of 70% ethanol. After air drying for 5 minutes, the beads and the DNA were 
resuspended in an appropriate volume of sterile deionized water. During this step the DNA 
elutes from the beads. The beads were separated from the DNA containing supernatant by 
incubation on the magnetic plate. The supernatant was carefully pipetted in a new tube and 
used immediately or stored at 4°C for short or -20°C for long term. 
2.2.1.4 DNA extraction from agarose gels 
After excision of DNA fragments from Broad Range agarose (Roth) gels with a scalpel the 
DNA was extracted using the QIAEX II Gel Extraction Kit (Qiagen) according to the 
manufacturers’ instructions. The supernatant containing the DNA was generally used 
immediately for downstream applications.  
2.2.1.5 Phenol/chloroform extraction and alcohol precipitation of nucleic acids (NAs) 
For the generation of transcription- and transfection-quality DNA and RNA templates the 
elimination of any possible enzyme contamination is crucial. Therefore the linearized 
plasmids and the in vitro transcribed RNAs were extracted using phenol/chloroform as 
described in (Sambrook et al. 2001) with following modifications: Mixing was always carried 
out by inverting the tubes in order to prevent shearing of the long (> 35 kb) NA fragments. 
DNA was precipitated preferably over night at -20°C or pelleted immediately. RNA was 
always stored at -20°C for at least 15 minutes, preferably overnight. 
RNA was always resuspended in Ambion water. For linearized plasmids the concentration 
was usually adjusted to 0.2 µg/µl. Concentration and purity of the samples was analyzed by 
agarose gel electrophoresis (2.2.1.6) and photometric analysis (2.2.1.7). 
The DNA was used immediately or stored at -20°C. RNA was stored at -70°C. 
2.2.1.6 Agarose gel electrophoresis of nucleic acids (NAs) 
NAs have a negatively charged phosphate backbone. Therefore they can be separated by 
agarose gel electrophoresis. According to their size and conformation the NA fragments 
migrate through the gel matrix differently. The smaller the fragments and the more 
supercoiled the conformation, the faster is the mobility towards the anode. 
The detection is performed with ethidium bromide which intercalates with nucleic acids and 
can be visualized by UV light. Samples were mixed with Loading Dye, the high content of 
sucrose keeps the aqueous NA solutions in the pocket of the gel and the dyes help 
visualizing the velocity of NA migration. 
For standard gels GTQ agarose (Roth) was weighed and dissolved in TAE buffer by heating. 
Preparative gels were prepared with Broad Range agarose (Roth) and sterile TAE buffer. 
Dissolved agarose was cooled down and supplied with 0.5 μg/ml ethidium bromide. Samples 
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and appropriate molecular weight markers (2.1.11) were loaded onto the gel. Generally 0.8-
2% agarose gels were used and run at 60-140 Volts. For some applications gels were 
stained with ethidium bromide or GelStar® Nucleic Acid Gel Stain (1:1000) post run. 
2.2.1.7 Photometric analysis of nucleic acid concentration 
Nucleic acids absorb monochromatic light and concentrations can thus be measured by 
photometry. Disposable plastic cuvettes (Eppendorf UVette®) with a thickness of 1 cm were 
used in a Biophotometer (Eppendorf). The blank was measured with a minimum of 50 μl 
water or the corresponding buffer. Samples were measured at a wavelength of 260 nm 
(maximum absorption of nucleic acids), 280 nm (maximum absorption of proteins and 
phenol) and 320 nm (maximum absorption of carbohydrates) to assess impurities.  
For DNA a result of one compared to the reference means a concentration of 50 μg/ml and 
for RNA 40 μg/ml, respectively. 
Formula for calculation: C = (E260 – E320) x d x f [μg/ml] 
C = concentration 
E = extinction 
d = dilution factor 
f = factor for DNA (50 μg/ml) and RNA (40 μg/ml) when using a 1 cm cuvette 
2.2.1.8 Sequencing of DNA 
Sequencing was done using the ABI PRISM® Big Dye® Terminator Cycle 
Sequencing Ready Reaction kit (Applied Biosystems) which is based on Sanger’s method 
(Sanger et al. 1977). The 5x Sequencing Buffer was diluted to 2,5x with HPLC H2O and 
stored at 4°C until usage. Big Dye Terminator Sequencing Ready Reaction Mix Version 3 
was always stored at -20°C in small aliquots and thawed immediately before use to prevent 
repeated freeze/thaw cycles. 
Templates for sequencing were obtained by generating PCR products (2.2.1.11) of the 
region of interest. Size, purity and quantity of the PCR products were analyzed using 
agarose gel electrophoresis (2.2.1.6) and purified using Ampure (see 2.2.1.3).  
Big Dye Mix was prepared freshly prior to sequencing PCR as listed in Table 1 for one 
reaction (1 rxn). 
Table 1: Big Dye Mix 
1 rxn  
1 µl  Big Dye Ready Reaction Mix (2.5x) 
3 µl  Sequencing Buffer (2.5x) 
 
Sequencing PCR reaction (see Table 2) was supplied with 4 µl of the Big Dye Mix. 
32 
Table 2: Big Dye sequencing PCR reaction 
1 rxn   
1-5 µl  PCR-Product up to 100 ng 
0-4 µl  H2O - 
1 µl  Primer (10 µM) 1 µM 
4 µl  Big Dye Mix (2,5x) 1x 
 
The reaction was cycled as specified in Table 3. 
Table 3: Big Dye sequencing PCR program 
96°C 3 min 1x 
96°C 30 sec 
25x 50°C 15 sec 
60°C 4 min 
 
The protocol was done as described in (Etchevers 2007) with minor modifications. 
PCR Products were purified with a quick clean up method using Sephadex G-50 superfine 
(GE Healthcare) and MultiScreen Filter plates (Millipore). 
Dry Sephadex was added to a column loader (Millipore) and applied to a MultiScreen plate 
(Millipore). 300 µl HPLC-H2O were added and the plate was incubated two hours at room 
temperature. After swelling, the excess water was removed by centrifugation (3000 rpm, 5 
minutes); the sequencing PCR products were added and eluted into a clean plate by 
centrifugation (3000 rpm, 5 minutes). HiDi™ Formamide (12 µl) and 4.5 µl of purified PCR 
reaction were added to each well of a PCR multiwell plate. The plate was covered with a 96 
well septum, centrifuged briefly and loaded in the 3100 Genetic Analyzer (Applied 
Biosystems). Processing was done according to the manufacturers’ instructions using a 50 
cm 16 capillary array with Performance Optimized Polymer POP-6. Settings for Dye Set Z 
and the default 50 cm POP-6 Run Module were chosen. 
2.2.1.9 In vitro synthesis of capped RNA 
For the in vitro synthesis or in vitro transcription (IVT) of capped full-length virus RNA the 
Ambion mMESSAGE mMACHINE® kit was used. The manufacturers’ protocol was adapted 
to long templates and high yield by supplying additional GTP, increasing the reaction volume 
and the incubation time: 
The 10x buffer, 2x NTP/Cap and GTP were thawed, mixed and centrifuged briefly prior to 
use. The 2x NTP/Cap, GTP and the enzyme mix were then placed on wet ice. Short term 
storage of the 10x buffer and the assembly of the reaction were done at room temperature 
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(Table 4).  
Table 4: mMessage mMachine IVT reaction setup 
1 rxn T7/SP6 (30 µl) Reagent 2 rxn SP6 (N) 
15 µl 2x NTP/Cap 20 µl 
3 µl 10x Buffer 4 µl 
4 µl GTP 2 µl 
3 µl Enzyme Mix 4 µl 
25 µl Sum 2x 15 µl 
5 µl Template (1 µg) 2x 5 µl 
 
Purified PCR products (2.2.1.3) or linearized plasmids (2.2.1.20) served as template DNA. 
The reactions were mixed by pipetting or flicking and spinning down. Reaction tubes were 
incubated at 37°C in an incubator or a heating block (Thermomixer, Eppendorf). After 
approximately 2 hours of incubation 1 µl Turbo-DNase was added and the reaction was 
mixed by tapping and spinning or pipetting. The enzymatic reaction was stopped after 15 
minutes by adding ammonium acetate stop solution and water (Table 5): 
Table 5: Stopping of in vitro synthesis 
1 rxn T7/SP6 Reagent SP6 (N, pool 2 rxn) 
30 µl Sum IVT reaction 40 µl 
15 µl AmAc Stop Solution 15 µl 
105 µl Ambion H2O 95 µl 
150 µl Total 150 µl 
 
Reactions were mixed by pipetting and purified by phenol/chloroform extraction and isopropyl 
alcohol precipitation according to 2.2.1.5.  
2.2.1.10 cDNA synthesis 
RNA dependant DNA polymerases like MMLV RT (Moloney Murine Leukemia Virus Reverse 
Transcriptase) synthesize cDNA from an RNA template. This process is called reverse 
transcription (RT). The SuperScript III® Reverse Transcriptase Kit was used in combination 
with RNaseOUT™ Recombinant Ribonuclease Inhibitor and RNase H (all Invitrogen). The 
protocol was based on the manufacturers’ instruction and adapted to long cDNA products. 
For the assembly of the reaction two master mixes were prepared (Table 6): 
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Table 6: Assembly of cDNA synthesis master mix 1 and 2 
Mix 1 1 rxn Mix 2 1 rxn 
dNTPs (10 mM) 1 µl (0.5 mM) 5x First Strand Buffer 4 µl 
Reverse Primer (10 µM) 1 µl (0.5 µM) 0.1 M DTT 1 µl (5 mM) 
H2O 4 µl (4-8 µl) Superscript III (200 U/µl) 2 µl (400 U) 
BSA (1 mg/ml) 1 µl (1 µg) RNase out (40 U/µl) 1 µl (40 U) 
RNA 5 µl (1-5 µl)   
Total 12 µl Total 8µl 
Total Mix 1 + 2 20 µl   
 
After assembly Mix 1 was mixed well by pipetting and heated to 65°C for five minutes using a 
thermocycler. This step allows denaturation of the RNA and annealing of the reverse primer. 
After cooling of Mix 1 to 4°C Mix 2 was added, the reaction was mixed by pipetting and 
heated to 55°C for 60 minutes to allow cDNA synthesis. The enzymes were inactivated at 
75°C for 5 minutes. After inactivation the reaction mix was cooled to 4°C. RNase H was 
added (1 µl, 2 U) to degrade the remaining RNA. The reaction was mixed by pipetting and 
incubated at 37°C for 15 minutes. cDNA was used immediately or stored at -20°C. 
2.2.1.11 PCR using Phusion Enzyme 
Generally PCRs were done using Phusion® High-Fidelity DNA Polymerase (Finnzymes). 
This enzyme is a Pyrococcus-like DNA-polymerase, combining a proofreading activity with 
enhanced processivity. PCR products have blunt ends and are therefore unsuitable for TA-
Cloning. The PCR was setup as listed in Table 7. 
Table 7: PCR setup using Phusion enzyme 
Reagent 1 rnx 
H2O to 25 µl 
5x Phusion HF Buffer 5 µl 
dNTPs (10 mM) 0.5 µl (0.2 mM) 
Forward primer (10 µM) 0.5 µl (0.2 µM) 
Reverse primer (10 µM) 0.5 µl (0.2 µM) 
Phusion (2 U/µl) 0.25 µl (0.5 U) 
Template 1-5 µl (1 pg-50 ng) 
 
Cycling was done as specified in Table 8. 
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Table 8: PCR program using Phusion enzyme 
Step Temperature Time 
Initial denaturation 98°C 20 sec 
30 cycles 
Denaturation 98°C 10 sec 
Annealing 58°C 20 sec 
Elongation 72°C 15 sec/ 1 kb 
   
Final elongation 72°C 30 sec/ 1 kb 
Cooling 4°C Forever 
2.2.1.12  PCR using Platinum Taq 
PCR products with A overhangs for TA cloning were generated with Platinum® Taq 
(Thermus aquaticus) Polymerase (Invitrogen). It has a non-template-dependent terminal 
transferase activity that adds a single deoxyadenosine (A) to the 3' ends of PCR products. 
Like standard Taq, it has both 5' to 3' polymerase and 5' to 3' exonuclease activity. PCR was 
setup as listed in Table 9 and the cycling program was done as specified in Table 10. 
Table 9: PCR setup using Platinum Taq 
Reagent 1 rnx 
H2O to 50 µl 
10x PCR Buffer 5 µl 
dNTPs (10 mM) 1 µl (0.2 mM) 
MgSO4 (50 mM) 2 µl 
Forward primer (10 µM) 1 µl (0.2 µM) 
Reverse primer (10 µM) 1 µl (0.2 µM) 
Platinum Taq (5 U/µl) 0.2- 0.5 µl (1- 2.5 U) 
Template 1-5 µl (1 pg-50 ng) 
 
Table 10: PRC program using Platinum Taq 
Step Temperature Time 
Initial denaturation 94°C 2 min 
35 cycles 
Denaturation 94°C 25 sec 
Annealing 55°C 25 sec 
Elongation 72°C 1 min/ 1 kb 
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2.2.1.13 PCR using Herculase enzyme 
Herculase II Fusion DNA polymerase was used to generate long PCR fragments from cDNA 
templates. The enzyme is Pfu-based (Pyrococcus furiosus) and has a proofreading activity 
(3’ to 5’ exonuclease activity). PCR was setup as listed in Table 11 and cycled according to 
Table 12. 
Table 11: PCR setup using Herculase enzyme 
Reagent 1 rnx 
H2O to 50 µl 
5x Herculase II Buffer 10 µl 
dNTPs (25 mM) 0.8 µl (0.4 mM) 
Forward primer (10 µM) 2 µl (0.4 µM) 
Reverse primer (10 µM) 2 µl (0.4 µM) 
Herculase II Fusion Polymerase 1 µl 
Template 1-10 µl cDNA 
 
Table 12: PCR program using Herculase enzyme 
Step Temperature Time 
Initial denaturation 94°C 2 min 
35 cycles 
Denaturation 94°C 15 sec 
Elongation 68°C 30 sec/ 1 kb 
 
2.2.1.14  One-step RT-PCR 
For the generation of PCR products directly from RNA, a one-step reverse transcription PCR 
(one-step RT-PCR) was used. One-step RT PCR Kits contain buffers, dNTPs and a mixture 
of two (or more) polymerases. The RNA-dependent DNA polymerase (reverse transcriptase) 
synthesizes the cDNA and a hot-start DNA-dependent DNA polymerase (Taq polymerase) 
exponentially amplifies the cDNA template. Hot-start Taq polymerases are inactivated by 
either antibodies or chemical modifications. Heating of the reaction mix to 95°C activates the 
enzyme, thus enabling an unbiased reverse transcription beforehand.  
One-step RT-PCRs using the QIAGEN OneStep RT-PCR Kit were setup as listed in Table 
13 and cycled according to Table 14. 
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Table 13: QIAGEN One-Step RT-PCR setup 
Reagent 1 rnx 
H2O to 25 µl 
5x OneStep RT-PCR Buffer 5 µl 
dNTPs (10 mM) 0.5 µl (0.2 mM) 
Forward primer (10 µM) 0.5 µl (0.2 µM) 
Reverse primer (10 µM) 0.5 µl (0.2 µM) 
OneStep RT PCR Enzyme Mix 1 µl 
Template 1-5 µl (1 pg-2 µg) 
 
Table 14: QIAGEN One-Step RT PCR program 
Step Temperature Time 
Reverse transcription (RT) 50°C 15-30 min 
Initial denaturation 95°C 15 min 
30-45 cycles 
Denaturation 95°C 15 sec 
Annealing 55°C 15 sec 
Elongation 72°C 1 min/ 1 kb 
Cooling 4°C Forever 
 
2.2.1.15  Real-time RT PCR 
The real-time RT PCR is a one-step RT PCR that allows the detection of amplification 
products in real-time during the amplification process. Special oligonucleotides linked with 
fluorescent dyes (probes) are added to the reaction mixture. The probes hybridize with the 
nascent PCR strands and fluorescent dyes are released by the 5’ to 3’ exonuclease activity 
of the Taq polymerase. These dyes can be detected during the cycle process using special 
real-time cyclers and the gain in fluorescence is diagrammed by special software. The cycle 
number, at which the fluorescence rises above the background or threshold level, is referred 
to as crossing point (Cp) or crossing threshold (Ct). By adding standard samples with known 
RNA concentration, the unknown samples can be quantified. In a logarithmic dilution series 
and under optimal PCR conditions the Cp between two ten-fold dilutions is 3.3. 
For the analysis of RNA in real-time the SuperScript™ One-Step RT-PCR with Platinum® 
Taq and the SuperScript® III One-Step RT-PCR System with Platinum® Taq DNA 
Polymerase Kits (both Invitrogen) were used. Table 15 shows the real-time RT PCR setup. 
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Table 15: Real-Time RT PCR setup 
Reagent 1 rnx 
H2O to 25 µl 
2x Reaction mix 12.5 µl 
MgSO4 (50 mM) 2 µl (4 mM) 
BSA (1 mg/ml) 1 µl (1 µg) 
Forward primer (10 µM) 0.5 µl (0.2 µM) 
Reverse primer (10 µM) 1 µl (0.4 µM) 
Probe (10 µM) 1 µl (0.4 µM) 
Superscript RT/Platinum Taq Mix 0.5 µl 
Template 5 µl 
 
The cycling conditions are listed in Table 16. 
Table 16: Real-Time RT PCR program 
Step Temperature Time 
Reverse transcription (RT) 45°C 20 min 
Initial denaturation 95°C 2 min 
45 cycles 
Denaturation 95°C 15 sec 
Annealing & Elongation 60°C 30 sec (acquisition) 
Cooling 40°C 30°C 
 
Samples were only stored for troubleshooting in case of doubtful results.  
2.2.1.16 Phusion mutagenesis PCR 
Positive clones up to a size of 15 kb were corrected or mutated using the Phusion™ Site-
Directed Mutagenesis Kit (Finnzymes). Primers were designed according to the 
manufacturers’ recommendations. The mutagenesis PCR was adapted to long products (see 
Table 17) and cycled as listed in Table 18. 
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Table 17: Phusion mutagenesis PCR setup 
Reagent 1 rnx 
H2O to 50 µl 
5x Phusion HF Buffer 10 µl 
dNTPs (10 mM each) 2 µl (0.4 mM) 
Forward primer (10 µM) 1 µl (0.2 µM) 
Reverse primer (10 µM) 1 µl (0.2 µM) 
Phusion Hot Start DNA Polymerase (2 U/µl) 1 µl (2 U) 
Template 1 µl (10-20 ng) 
 
Table 18: Phusion mutagenesis PCR program 
Step Temperature Time 
Initial denaturation 98°C 30 sec 
25 cycles 
Denaturation 98°C 10 sec 
Annealing 58-62°C 20 sec 
Elongation 72°C 30 sec/ 1 kb 
   
Final elongation 72°C 45 sec/ 1 kb 
Cooling 4°C Forever 
 
Mutagenesis PCR Products were analyzed using agarose gel electrophoresis and ligated 
according to Table 19. 
Table 19: Phusion mutagenesis ligation setup 
Reagent 1 rnx 
H2O to 10 µl 
PCR Product 1 µl (25 ng) 
2x Quick Ligation Buffer 5 µl 
Quick T4 DNA Ligase 0.5 µl 
 
The ligation reaction was incubated for not longer than 2 hours at room temperature, then 
chilled on wet ice and either used immediately for transformation of E. coli cells or stored at -
20°C. Transformation and downstream applications were done as depicted in chapter 
2.2.1.22 and 2.2.1.24. 
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2.2.1.17 Quick Change mutagenesis PCR  
Positive clones up to a size of 10 kb were corrected or mutated using the QuickChange® II 
XL Site-Directed Mutagenesis Kit (Stratagene) following the instruction manual. Primers were 
designed according to the manufacturers’ recommendations.  
2.2.1.18 Sequencing and genome size verification using Phusion polymerase 
For verification of full-length pBelo BACs and generation of PCR products for sequencing, 
eight PCRs were performed per full-length BAC. The PCR setup was done as described in 
2.2.1.11, primers were used as listed in Table 20. The calculated product sizes were 
compared with the PCR product sizes using agarose gel electrophoresis (2.2.1.6). 
Table 20: Phusion polymerase PCR primers and products for sequencing and genome size verification 
No Primer fw Primer rev Product size (bp) 
1 pBSCrev 4000R 4219 
2 3370F 7520R 3780 
3 7010F 11531R 4583 
4 10458F 14629R 4207 
5 14040F 18086R 4026 
6 17903F S22016R 4157 
7 21637F 25644R 4029 
8 24465F pBSCfw 3257 
 
2.2.1.19 RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE) 
The RLM-RACE is a method for sequencing and cloning of unknown 5’ and 3’ ends from viral 
RNA or mRNA. The GeneRacer™ Kit (Invitrogen) was used and primers were designed 
according to the manufacturers’ instructions.  
The 5’ and 3’ end PCR products they were either sequenced directly or first cloned and 
subsequently sequenced. 
2.2.1.20 Restriction and dephosphorylation 
Restriction enzymes cut DNA at or in the vicinity of a specific recognition site. Using 
enzymes that leave non-compatible 3’ or 5’ overhangs in vector and insert DNA allows 
unidirectional cloning. Screening for orientation is obsolete.  
Dephosphorylation means the hydrolysis of the 5’ phosphate of DNA. Vector DNA was 
dephosphorylated in order to prevent religation. As the 5’ phosphate is necessary for a 
successful ligation only plasmids with inserts should be formed. 
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Restriction was done according to the manufacturers’ instruction. If possible and proved 
functional, double digestion was performed. Fast Digest (Fermentas) enzymes were applied 
with a ratio of one Unit per microgram DNA. All other enzymes were applied in excess paying 
tribute to the supercoiled nature of the template plasmid DNA. Restriction success was 
monitored by agarose gel electrophoresis (2.2.1.6). 
After restriction the fragments were dephosphorylated if necessary, purified and 
concentrated by alcohol precipitation and separated by agarose gel electrophoresis (2.2.1.6), 
excised and extracted (2.2.1.4). Subsequent downstream applications, usually ligations, 
were initiated immediately. For short term storage the restriction reaction was frozen as a 
mixture with salt and alcohol (see 2.2.1.5) at -20°C. 
2.2.1.21 Ligation 
Ligation of DNA fragments was either done according to the Kit manufacturers’ instructions 
or with T4 DNA Ligase (high concentrated, 5 U/µl) (Roche) as listed in Table 21. 
Table 21: Ligation setup with Roche T4 DNA ligase 
Reagent 1 rxn 
10x Ligase buffer 1 µl 
DNA fragments 0.5 - 7.50 µl 
H2O 0 - 7 µl 
DNA ligase 1:10 (0.5 U/µl) 1.5 µl (0.75 U) 
 
The ligation reactions included up to three different DNA fragments. They were incubated for 
>16 hours (overnight) at 14°C and used for the transformation of E. coli cells without further 
modification or inactivation (see 2.2.1.22, 2.2.1.24). 
2.2.1.22 Cloning 
The TOPO TA Cloning® Kit for Sequencing (Invitrogen) was used for TA cloning according 
to the manufacturers’ instructions. The CloneSmart® Blunt LC Cloning Kit (Lucigen) was 
used for blunt end cloning according to the manufacturers’ instructions.  
Cloning with the pBelo BAC (2.1.12) comprised different modifications of the vector for the 
adaptation to the HCoV-NL63 cloning strategy. For this approach modified pBelo BAC11 
vectors pBelodNco3 and pBeloAd4 were used.  
Vector pBelodNco3 was created by excision of 613 bp, containing the multiple cloning site 
(MCS), from pBelo BAC11 using a digestion with NotI. A new MCS was introduced by an 
oligonucleotide adapter containing NsiI, BsaHI, SphI and NotI restriction sites in sequence, 
resulting in pBeloAd4.The excision of cos, loxP and lacZ containing the MCS as well as the 
addition of a new multiple cloning site was done as described previously (Pfefferle et al. 
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2009).  
2.2.1.23 Preparation of media for bacteria culture 
Media for the cultivation of bacteria were prepared according to the manufacturers’ 
instructions. The pre-mixed dry medium was weighed, dissolved in an appropriate volume of 
deionized water and autoclaved (120°C and 1 bar pressure). LB agar was cooled to 50°C, 
supplemented with the appropriate antibiotics and poured into Petri dishes. After cooling for 
several hours the plates were stored at 4°C. LB broth was only used intermittently and 
therefore stored at 4°C without antibiotics. These were added from stock solutions 
immediately before use to guarantee full effectiveness. Antibiotics from stock solutions were 
added to a concentration of 50 µg/ml (carbenicillin, kanamycin) and 12.5 µg/ml 
(chloramphenicol) in working solution. 
2.2.1.24 Production of competent E. coli cells and transformation 
For transformation of E. cloni 10G electrocompetent cells and One Shot® TOP10 chemically 
competent cells original stocks were used. 
One Shot® Stbl3™ chemically competent cells were initially purchased and then generally 
produced in-house: 
Conical flasks containing LB medium were inoculated with 1/1000 (v/v) of an overnight E. coli 
culture. The culture was grown at 37°C with 160 rpm (GFL-3033) until an OD600 of 0.5-0.7 
was reached (after approximately 2 hours). Cells were cooled down shaking on wet ice and 
incubated at 4°C for 15 minutes. They were harvested by centrifugation at 4°C and 3000 rpm 
in a pre-cooled centrifuge (Sorvall Evolution RC) for 15 minutes. The supernatant was 
discarded; cells were resuspended in 50 ml of 80 mM CaCl2 on wet ice and incubated at 4°C 
for 40 minutes. Cells were pelleted again as described above. The supernatant was removed 
carefully and the cells were resuspended in 5 ml 80 mM CaCl2 supplemented with 20% 
glycerol. Aliquots of 100 µl were dispensed in pre-chilled 1.5 ml reaction tubes and deep-
frozen immediately using either liquid nitrogen or dry ice. Aliquots were stored at -70°C until 
usage. Test transformations were done with a pUC19 plasmid originally provided by the 
manufacturer (Invitrogen). Electrocompetent E. cloni cells were transformed according to the 
manufacturers’ instructions using the Gene Pulser Xcell (Bio-Rad). 
Chemically competent cells were thawed completely on wet ice, in-house produced Stbl3 
were split in two 50 µl aliquots and commercially supplied cells were treated as indicated in 
the manual. Up to 5 µl (or 100 ng) of plasmid DNA or a ligation reaction were added to the 
cells and mixed by gentle stirring with the pipette tip. Cells were incubated on ice for 30 
minutes and heat-shocked for 30 or 45 seconds in a heating block (Thermomixer comfort, 
Eppendorf). Immediately after the heat shock cells were incubated on ice for two minutes. 
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275 µl of pre-warmed S.O.C. medium was added to the cells and they were further incubated 
at 37°C for one hour in a heating block at 350 rpm (Thermomixer comfort, Eppendorf). Cells 
were spread on selective agar plates using different volumes and incubated over night at 
37°C. Single colonies were transferred to fresh plates with appropriate antibiotics and 
incubated until plasmid DNA preparation (2.2.1.2) or additionally directly screened by PCR.  
2.2.1.25 High-copy plasmid culture 
E. coli (TOP10) containing high-copy plasmids like pCR 2.1 were either cultivated on one 
eighth of a selective agar plate or in 2 ml of LB broth supplemented with the appropriate 
antibiotics. The cells were incubates over night at 37°C and harvested as described in 
2.2.1.2. 
2.2.1.26 BAC culture 
Cultivation of E. coli (Stbl3, E. cloni) containing BACs was always done using agar plates. 
For small scale plasmid DNA preparation one quarter of a selective agar plate was 
inoculated with bacteria from a single colony. For medium scale plasmid DNA preparations 
five to ten agar plates were plated. The bacteria were incubated over night at 37°C and 
harvested as described in 2.2.1.2. 
2.2.2 Cell culture Methods 
2.2.2.1 Preparation of media and solutions 
Cell culture media and solutions were always prepared under sterile conditions. If possible 
commercially available, sterile and endotoxin free products were used.  
Fetal calf serum (FCS) was inactivated for 30 minutes at 56°C, sterilized by filtration 
(Stericup, Millipore) and stored in 50 ml aliquots at -20°C until usage. 
Dulbecco´s Modified Eagles Medium (DMEM) was supplemented with 100 ml/l FCS, MEM 
NEAA (L-alanine 890 mg/l, L-asparagine 1320 mg/l, L-aspartic acid 1330 mg/l, L-glutamic 
acid 1470 mg/l, L-glycine 750 mg/l, L-proline 1150 mg/l, L-serine 1050 mg/l), L-glutamine (2 
mM), sodium pyruvate (1 mM) and penicillin/streptavidin (100 Units/ml and 0.1 mg/ml) under 
sterile conditions (2.1.6.1). 
OptiPro SFM was supplemented with, L-glutamine (2 mM) and penicillin/streptavidin (100 
Units/ml and 0.1 mg/ml) under sterile conditions. 
Double concentrated DMEM (2x DMEM) was produced by adding 13.54 g/l powdered DMEM 
(Biochrom) to a bottle of liquid DMEM. Supplements were added in double concentration, 
200 ml/l FCS, MEM NEAA (L-Alanine 1780 mg/l, L-Asparagine 2640 mg/l, L-Aspartic Acid 
2660 mg/l, L-Glutamic Acid 2940 mg/l, L-Glycine 1500 mg/l, L-Proline 2300 mg/l, L-Serine 
2100 mg/l), L-glutamine (4 mM), sodium pyruvate (2 mM) and penicillin/streptavidin (200 
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Units/ml and 0.2 mg/ml) (2.1.6.1). This double concentrated DMEM was sterilized by filtration 
(Stericup, Millipore). 
1x PBS was obtained by diluting 100 ml/l 10x PBS (Accugene) with deionized water. The 
solution was sterilized by filtration (Stericup, Millipore). 
Avicel and plaque agarose overlays were prepared as follows (2.1.6.1): 2.4% Avicel® RC581 
(w/v) was dissolved in deionized water and autoclaved (120°C and 1 bar pressure). 2% 
Plaque Agarose (w/v) was added to deionized water and autoclaved (120°C and 1 bar 
pressure). The sterile solutions were stored at room temperature.  
CMC granules were weighed according to the desired volume of overlay medium to a 
concentration of 1.6% (w/v) and autoclaved (120°C and 1 bar pressure). Prior to use the 
sterile CMC was dissolved by stirring in sterile DMEM over night (2.1.6.1). 
Unless otherwise noted all media and solutions were stored at 4°C until usage; supplements 
were stored as indicated by the manufacturer. 
2.2.2.2 Cell culture conditions 
All cell lines were grown at 37°C and 5% CO2 in DMEM. Either cell culture flasks with filter 
caps or cell culture plates were used for the propagation of cells lines. 
2.2.2.3 Cultivation of cell lines 
All cell lines were split one to two times a week at a ratio of 1:2 up to 1:10 according to the 
experimental needs. Cells were washed with PBS, trypsin was added and cells were 
incubated at 37°C and 5% CO2 until detachment. The enzymatic process was stopped by 
adding DMEM containing 10% FCS. Cells were counted and subsequently diluted or first 
concentrated by centrifugation and then diluted according to the cell numbers to be seeded.  
In order to avoid prolonged trypsinization, CaCo-2 cell lines were alternatively detached by 
scraping. 
2.2.2.4 Cryopreservation of cell lines 
For long-term storage in liquid nitrogen cells were cryopreserved in medium containing 10% 
DMSO (v/v), 40% DMEM (v/v), 50% FCS (v/v). Before adding the cryopreservation medium 
cells were trypsinized, washed and counted. 1-5 x 106 cells were added to each cryovial.  
Thawing of cell lines was done quickly at 37°C and 5% CO2. Cells were resuspended in fresh 
medium, transferred to a sterile 15 ml reaction tube and pelleted at 1000 rpm (5804R, 
Eppendorf). The cell pellet was resuspended in fresh medium and transferred to a cell 
culture flask with filter cap. Medium was changed the next day or after cells became 
adherent. 
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2.2.2.5 Transfection of mammalian cells by electroporation 
For the transfection of mammalian cells 175 cm² flasks were seeded and grown to 70-80% 
confluency. Cells were washed with PBS and trypsinized. Trypsin was inactivated by addition 
of DMEM with 10% FCS. Cells were counted and washed twice with ice cold PBS. Washing 
was done by resuspension of the cells and centrifugation for 5 minutes at 4°C and 1200 rpm 
(5804R, Eppendorf). After the last centrifugation step the supernatant was removed 
completely by aspiration. The cell number was adjusted to 2x 107 cells/ml with ice cold PBS 
or Opti-MEM and stored on ice until usage. For each transformation 100-400 µl of the cell 
suspension were mixed with in vitro transcribed (IVT) RNA (see 2.2.1.9) and transferred to 
an electroporation cuvette with 2 mm gap. Pulse was applied as listed in Table 22. 
Table 22: Electroporation protocols for mammalian cells 
Program Cell line Volts µF msec Ohms nP Method 
BHK21 BHK21 140 - 25 - 1 Square wave 
CaCo2 CaCo-2 300 950 - ∞ 1 Exponential decay 
CaCo2b CaCo-2 1500 25 - ∞ 2 Exponential decay 
CV1 LLC-MK2 100 - 25 - 1 Square wave 
LLC-MK2 LLC-MK2 200 950 - ∞ 1 Exponential decay 
 
After electroporation, cells were incubated for 10 minutes at room temperature and then 
transferred to 25, 75 or 175 cm² flasks containing 6-30 ml DMEM. Samples were taken after 
seeding into the flasks and every 2-3 days during incubation.  
2.2.3 Virus culture methods 
2.2.3.1 HCoV-NL63 virus stock 
An eighth passage virus stock of HCoV-NL63 was kindly provided by Lia van der Hoek, AMC 
Amsterdam. It was grown in LLC-MK2 cells in limiting dilution series, recovering it three times 
from the last well of a dilution series still showing diffuse CPE. Subconfluent LLC-MK2 
monolayers were infected in 75 cm² flasks with virus supernatant from the last round of 
limiting dilution culture at a ratio of 1:100 (200 µl virus supernatant in 20 ml fresh medium) as 
described in 2.2.3.2. The flasks were incubated at 37°C, 5% CO2, and harvested on day four. 
For harvesting, flasks were frozen at -70°C and thawed. Cells and supernatant were 
centrifuged for 10 min at 5000 rpm. Cleared supernatant was aliquoted and stored at -70°C. 
This virus stock is hereafter referred to as LLC-MK2 NP (for non-purified).  
This virus stock was the parental stock for all non-recombinant viruses like the CaCo-2-
adapted virus and served as template for the recombinant BACs and viruses. All stocks from 
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modified or adapted viruses were prepared as depicted above. 
2.2.3.2 Infection of cells  
Cells were seeded (2.2.2.3) in six-well plates at approximately 4 x 105 cells per well (24-well 
plates: approximately 105 cells per well) and incubated (2.2.2.2) until the monolayer was 70-
80% confluent. CaCo-2 cells were grown to 100% confluence. Prior to infection cells were 
washed with 1x PBS. Virus dilution was prepared in OptiPro serum free medium (Invitrogen), 
six-well plates were infected with a volume of 1 ml, 24-well plates with 500 µl, respectively. 
Inoculum was removed after one hour of incubation. Cells were washed twice with 1x PBS 
and supplemented with an appropriate volume of DMEM or overlay medium per well. Cells in 
cell culture flasks were treated and infected correspondingly.  
2.2.3.3 Overlays 
For CMC overlays using six-well plates, 1 ml DMEM was added to each well. Subsequently 1 
ml of 1.6% CMC solution was slowly added per well (2.2.2.1). Using 24-well plates 500 µl 
were used instead of 1 ml. Agarose overlays (1% final concentration) were prepared by 
melting 2% agarose at 70°C, cooling it in a water bath to 42°C and mixing it immediately 
before application with an equal volume of 2x DMEM stored at room temperature (2.2.2.1). 
Two ml of the mixture were carefully applied to each well using six-well plates; 1 ml was 
added per well using 24-well plates. Avicel overlays were made by mixing 2.4% Avicel 
solution with an equal volume of 2x DMEM (2.2.2.1). 2 ml of the mixture were immediately 
added to each well using six-well plates, 1 ml was used for 24-wells, respectively. 
2.2.3.4 Plaque assays 
Plaque assays were incubated without disturbing at 37°C and 5% CO2. (2.2.2.2) Overlays 
were commonly removed on day five and cells were fixed with a solution of 4% formaldehyde 
in PBS. After 30 minutes the formaldehyde solution was removed, cells were washed twice 
with PBS, and stained with a 0.2% crystal violet solution (2.1.4). 
2.2.3.5 Limiting dilution infection series and plaque purification 
Limiting dilution infections were done on six-well plates. For plaque purification the cells were 
overlaid with plaque agarose. After 5 days, cytopathic foci were identified by microscopy at 
low magnification, lighting through the clear agarose overlay. The positions of CPE foci were 
marked. The agarose overlay was penetrated with a pipette and 10 to 20 µl of fluid were 
aspirated underneath the overlay. This fluid was resuspended in 100 µl of OptiPro, which 
served as the starting solution for a new limiting dilution infection in the next six-well plate. 
After the last round, aspirated fluid was used to inoculate 5 ml of OptiPro, which was then 
overlaid on confluent cells in a 25 cm² flask for infection. After infection for one hour and 
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washing, 5 ml DMEM were added and flasks were incubated at 37°C, 5% CO2 for four days. 
Virus stocks were prepared as described in 2.2.3.1. 
For limiting dilution series without an overlay, 100 µl supernatant of the last well with visible 
CPE after 5 days were used for the next limiting dilution infection series. This was repeated 
for 3-10 times, after the last round virus stock was produced as described above. 
2.2.4 Immunodetection assays 
2.2.4.1 Spotting of HCoV-NL63 slides 
LLC-MK2 cells were infected as described above (2.2.3.1 and 2.2.3.2) and harvested after 
four days: Supernatant was removed, aliquoted and stored at -70°C. Infected and uninfected 
cells were washed with PBS and trypsinized. Trypsin was inactivated and cells were mixed at 
a ratio of 2:1 (infected: uninfected). This mixture was pelleted and washed three times with 
PBS. The cell pellet was resuspended in PBS and spotted on slides by pipetting and 
immediate re-aspiration. The slides were dried overnight and placed in aluminum pouches. 
Vacuum was applied to the pouches; they were sealed and stored at -20°C until usage. 
2.2.4.2 Immunofluorescence 
For the detection and proof of virus replication an indirect immunofluorescence assay (IFA) 
can be used. Monolayers of cells are grown and after infection fixed to glass slides by using 
different fixatives. Whereas PFA maintains cell structures and protein epitopes by building 
protein networks, fixation with methanol and acetone results in relatively strong 
defragmentation of membrane systems. After fixation the cells are incubated with primary 
and secondary antibodies. The secondary antibodies are labeled with fluorophores and can 
therefore be detected by fluorescence microscopy. 
2.2.4.3 Detection of HCoV-NL63 strain Amsterdam1 and recombinant HCoV-NL63 by 
immunofluorescence assay (IFA) 
LLC-MK2 or CaCo-2 cells were seeded on glass slides in a 24-well plate (8x 104 cells/well) 
and infected with HCoV-NL63 (2.2.3.2). Three to four days after the infection the cells were 
fixed with PFA (4%) for 15 minutes, permeabilized with 0.1% Triton X-100 for 10 minutes. 
Subsequently the cells were washed twice with phosphate buffered saline Tween 20 (PBST), 
blocked with PBST containing 3% FCS for 30 minutes at room temperature and washed 
again twice with PBST. Primary antibody, diluted 1:100 in PBS was added and incubated at 
37°C for 1 hour. For the detection of different viral proteins (M, N) peptide generated rabbit 
antisera (2.1.10.1) and patients’ sera were applied. Cells were washed twice with PBST and 
the secondary antibody (2.1.10.2) was added and incubated at 37°C in a wet chamber for 30 
minutes. Slides were mounted with DakoCytomation Fluorescent Mounting Medium and 
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analyzed by inverted fluorescence microscopy (Leica DM IL). 
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3  Results 
This work aimed at the construction of a full-length HCoV-NL63 cDNA clone. A prerequisite 
was a high degree of sequence stability and correctness of the cDNA clone. The subsequent 
transfection of genome-like full-length RNA into the cytosol of the host cell should mimic a 
natural infectious cycle. Therefore the advantage of a continuous full-length viral genome 
sequence embedded into a BAC was combined with a T7-driven in vitro transcription of 
infectious, capped full-length RNA, and a subsequent electroporation in mammalian cells. 
In our laboratory an approach for the construction of a full-length cDNA clone of SARS-CoV 
using a pBelo BAC vector backbone was already established (Pfefferle et al. 2009). For 
HCoV-NL63 a similar approach was chosen. The cloning strategy included a parallel 
subcloning into a pSMART as well as a pBelo BAC vector backbone with identification of and 
focusing on the more efficient method. The final full-length clone ought to be reconstructed 
gradually from the subclones, using a pBelo BAC backbone. 
3.1 Sequencing of the parental HCoV-NL63 Amsterdam 1 
The construction of a cDNA clone-based on reverse transcribed virus RNA is error-prone. 
When using M-MLV reverse transcriptase, for example, errors occur every 30,000 bases 
(Roberts et al. 1989). To assure the construction of a full-length clone with a sequence 
corresponding to the sequence of the viable HCoV-NL63 strain Amsterdam 1 kindly provided 
by Lia van der Hoek (van der Hoek et al. 2004), sequencing of the parental HCoV-NL63 
strain was done in parallel to the construction of subclones.  
An initial virus stock was produced from the HCoV-NL63 strain Amsterdam 1 using LLC-MK2 
cells (2.2.3.1). Slides were spotted with a mixture of infected and uninfected cells (2.2.4.1). 
A productive infection was proven by real-time RT PCR (2.2.1.15, data not shown) and an 
immunofluorescence assay (IFA, 2.2.4.2) of the cells using patients’ serum as primary 
antibody (see Figure 8). 
This virus stock, designated HCoV-NL63 LLC-MK2 NP (for non-purified), served as the origin 
of all virus stocks generated in this work using infectious cDNA clones or conventional cell 
culture methods. The virus RNA extracted from this stock served as template for all 
subsequent sequencing and the assembly of the full-length clone. Sequencing primers were 
designed based on the sequence of HCoV-NL63 Amsterdam 1 (GenBank accession number 
NC_005831). 
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Figure 8: Indirect immunofluorescence of HCoV-NL63 infected LLC-MK2 cells 
A: HCoV-NL63 infected LLC-MK2 cells incubated with HCoV-NL63 positive serum. Secondary antibody (Goat 
Anti-Human IgG, H & L Chain Specific Fluorescein Conjugate ) was added and fluorescence was detected and 
documented using a fluorescence microscope with camera. B: Negative control on the same slide as A. HCoV-
NL63 infected LLC-MK2 cells incubated with HCoV-NL63 negative serum. Secondary antibody, detection and 
documentation were done as described for A. The white bar corresponds to 50 µm 
 
The subclones were constructed as described below; positive clones were sequenced 
(2.2.1.8). The sequencing data was compared to the NCBI GenBank entry NC_005831 from 
HCoV-NL63 Amsterdam 1. In case of discrepancy the questionable part of the genome 
sequence was reamplified freshly from viral RNA by one-step RT PC (2.2.1.14) and 
sequenced. Overall, the RNA showed seven point mutations compared to the HCoV-NL63 
Amsterdam 1 sequence deposited in GenBank (Table 23). 
Table 23: Sequence comparison between HCoV-NL63 LLC-MK2 NP and GenBank accession number 
NC_005831 (Version NC_005831.2). Nucleotide position is based on the GenBank accession number 
NC_005831. * double peaks with underlying C-peak. 
Position 
NC_005831 
Base 
NC_005831 
Base  
LLC-MK2 NP 
Amino acid 
NC_005831 
Amino acid  
LLC-MK2 NP 
327 C T* Serine Leucine 
2956 T A Proline Proline 
2977 T A Alanine Alanine 
12477 C T Cysteine Cysteine 
16875 C T* Threonine Isoleucine 
22525 C T Alanine Valine 
23466 C A* Glutamine Lysine 
 
All four mutations leading to a change in the amino acid code at nucleotide position 327, 
16875, 22525 and 23466 were corrected on the subclone level (see below). Silent mutations 
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at positions 2956, 2977 and 12477 remained unchanged and served as marker mutations for 
the identification of recombinant DNA and RNA. 
3.2 Susceptibility of different cell lines to HCoV-NL63 and cytopathogenic 
effects 
LLC-MK2 and Vero cells did not cause a clear cytopathogenic effect (CPE) after infection 
with HCoV-NL63. Because this virus uses the same receptor as the SARS-CoV, 12 different 
cell lines susceptible to SARS-CoV infection were tested for susceptibility to HCoV-NL63 
(Weingartl et al. 2004; Hattermann et al. 2005; Yamashita et al. 2005) (Table 24). Cells in 
six-well plates were infected with 104 plaque-forming units of HCoV-NL63 virus stock LLC-
MK2 NP. RNA concentrations in supernatants were measured shortly after virus adsorption 
(2.2.3.2), and 7 days later (Table 24).  
Table 24: Comparison of HCoV-NL63 replication by real time RT-PCR using different cell cultures. 
Designation  
(see 2.1.6.2)  
Day 0 
[copies/µl] 
Day 7 
[copies/µl] 
Amplification 
factor 
Cytopathogenic effect (CPE) 
Vero E6 6.94e3 3.05e7 4.39e3 None 
Vero FM 1.78e4 4.51e9 2.54e5 None 
CaCo-2 
 
3.55e3 1.25e10 3.54e6 round and detached, dead 
cells with cell debris in 
supernatant, strong effect 
Calu1 2.61e4 5.33e6 2.04e2 None 
Calu6 7.95e3 5.00e5 6.29e1 None 
POEK 8.11e4 3.03e5 3.74e0 None 
PK13 2.66e2 7.78e5 2.93e3 None 
293lp 3.67e3 3.09e7 8.42e3 None 
FeA 1.45e4 5.83e5 4.03e1 None 
RD 3.14e5 1.57e4 4.99e-2 None 
PS 1.20e4 1.44e6 1.19e2 None 
LLC-MK2 4.00e3 2.65e6 6.62e2 round and detached,        
weak effect 
 
Increase of virus RNA was less than 1000-fold in 7 of 12 cultures. Interestingly, this included 
LLC-MK2, the prototype cell culture for NL63. In spite of a low amplification factor these cells 
showed the usual weak CPE that is typically observed upon HCoV-NL63 infection.  
Vero cells supported virus growth efficiently but did not result in CPEs. Interestingly, there 
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was a remarkable difference between Vero E6 and Vero FM cells (Table 24). In our hands 
these cells also showed differences upon SARS-CoV infection (data not shown). Vero FM 
consistently showed a more pronounced CPE than Vero E6 but there were no significant 
differences in RNA amplification (not shown).  
CaCo-2 cells amplified virus RNA most efficiently, and showed a clearly visible CPE starting 
from day 4 after infection. Cells became rounded, detached from the surface, and showed 
morphological signs of cell death (Figure 9).  
 
 
Figure 9: Cytopathogenic effect of HCoV-NL63 on human colon carcinoma cells (CaCo-2). 
CaCo-2 cells 5 days after infection with HCoV-NL63 at a multiplicity of infection of 0.1 (agarose overlay 
technique). A: mock infection, B: infection. Photographs were taken at 40-fold magnification; bars represent 20 
µm. 
 
For confirmation of differential replication efficiencies, CaCo-2 and LLC-MK2 cells were 
infected in parallel. Both cell lines were seeded in 25 cm2 flasks, and infected at multiplicities 
of infection (MOI) of 0.005. Samples of supernatants were taken daily from day 0 to 7 and 
analyzed by real time RT-PCR. As shown in Figure 10, CaCo-2 cells replicated virus more 
efficiently than LLC-MK2.  
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Figure 10: Growth kinetics of HCoV-NL63 on LLC-MK2 and CaCo-2 cells. 
25 cm
2
 flasks of LLC-MK2 or CaCo-2 cells were infected at multiplicities of infection of 0.005 for 1 h, washed 
twice with PBS, and subsequently supplied with 10 ml DMEM. Samples were taken daily from day 0 to 7 (except 
day 4) and analyzed by real time RT-PCR. Error bars indicate ranges of three independent experiments. 
 
From day 3 onward, RNA concentrations were more than 100-fold higher in CaCo-2 cells. 
Because of the clear CPE observed in CaCo-2 cells, these cells were tested for their utility in 
a cytopathogenic plaque assay. 
3.3 Comparison of different plaque assay overlays  
Three overlay techniques, commonly used for plaque assays, were tested for their suitability 
(Matrosovich et al. 2006). CaCo-2 cells were infected in six-well plates with HCoV-NL63 
LLC-MK2 NP. After one hour, supernatants were removed, cells washed with PBS, and 
overlaid in parallel with CMC, agarose and Avicel as described in 2.2.3.3. The plaque assays 
were fixed and stained as described in 2.2.3.4. As shown in Figure 11, plaques were visible 
with all three overlays, but staining was clearest with Avicel.  
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Figure 11: Plaque assay for HCoV-NL63 on CaCo-2 cells using different overlays. 
HCoV-NL63 was serially diluted on CaCo-2 cells (10
-1
 until 10
-5
). After 1 h of virus adsorption different overlays 
were added. After 5 days cells were fixed with 4% formaldehyde and stained with 0.2% crystal violet solution. A) 
carboxymethyl-cellulose; B) agarose; C) Avicel. 
 
3.4 Optimization of incubation times  
HCoV-NL63 culture with LLC-MK2 cells takes more than 7 days until first signs of weak CPE 
become visible (Fouchier et al. 2004). In order to test whether incubation times could be 
reduced with CaCo-2 cells, five plaque assays on virus dilution series were done with Avicel 
overlays and terminated by fixation after 1, 2, 3, 4, and 5 days, respectively. On days 1 and 
2, no plaques were visible (not shown). Termination at day 3 yielded plaques only at high 
virus concentration (Figure 12).  
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Figure 12: Plaque assays with different incubation times. 
Plaque assays were performed with Avicel overlay and incubated for 3, 4, and 5 days, respectively. The dilution 
factor of LLC-MK2 NP virus stock used for infection is shown on the bottom.  
 
From day 4 onward, plaques were visible in the lowest detectable virus concentration. 
Plaques on day 5 were larger, but did not increase in number. For all subsequent 
experiments fixation was done at 4 dpi. 
3.5 Plaque preparation  
In order to obtain virus stock solutions with higher infectivity, our standard virus stock LLC-
MK2 NP (2.2.3.1) was plaque-purified using the agarose overlay. Because life staining of 
cells with neutral red solution was not successful on CaCo-2 cells (not shown), we used an 
alternative technique of plaque preparation.  
Limiting dilution infections were done on six-well plates and were overlaid with agarose. After 
5 days, cytopathic foci were identified by scanning through the wells with the naked eye. 
Plaques were visible as turbid foci in the cell monolayer through the clear agarose overlay. 
The positions were marked and checked for a CPE with an inverted microscope at low 
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magnification. Plaque purification was done as described in 2.2.3.5. 
Three rounds of purification were done. After the last round, a virus stock was produced in a 
25 cm2 flask with a confluent CaCo-2 monolayer as described in 2.2.3.1. The purified virus 
was referred to as CaCo-2 PP (for plaque-purified). 
To compare the infectivity of the plaque-purified virus with the parental LLC-MK2 virus stock 
(LLC-MK2 NP), viral titers were determined by Avicel plaque assay. Results are shown in 
Figure 13.  
 
 
Figure 13: Effect of plaque purification. 
A: plaque assay with Avicel overlay on purified virus stock CaCo-2 PP. B: plaque assay on non-purified virus 
stock LLC-MK2 NP. C, viral RNA copies per ml of supernatant (left) and plaque forming units per ml of 
supernatant (right) for CaCo-2 PP and LLC-MK2 NP virus stocks (log scale). Error bars show ranges of three 
independent experiments. 
 
CaCo-2 PP was about 10-fold more infectious than LLC-MK2 NP. Plaque assays were 
repeated three times (not shown). Mean titers were determined to be 1.4 x 106 PFU/ml and 
1.3 x 105 PFU/ml, respectively, for CaCo-2 PP and LLC-MK2 NP. Absolute quantification of 
virus RNA by real-time RT-PCR yielded 4.8 x 1011 RNA copies/ml for CaCo-2 PP and 5.3 x 
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1010 copies/ml for LLC-MK2 NP. The high discrepancy between PFU/ml and RNA copies/ml 
could result from generation of defective interfering particles. 
3.6 Adaptation of HCoV-NL63 to CaCo-2 cells and full genome sequencing 
The HCoV-NL63 stock CaCo-2 PP was further adapted to CaCo-2 cells by ten consecutive 
limiting dilution infection series (2.2.3.5), followed by the production of a new virus stock on 
CaCo-2 cells (2.2.3.1). This stock was designated HCoV-NL63 CaCo-2 LD (for limiting 
dilution). 
A plaque assay was carried out on CaCo-2 six-well plates and repeated two times on 24-well 
plates. The mean titer was determined to be 3.1 x 106 PFU/ml for HCoV-NL63 CaCo-2 LD. 
Compared to HCoV-NL63 CaCo-2 PP the infectivity increased more than double. This new 
CaCo-2 adapted virus was fully sequenced and the genome was compared to the parental 
strain HCoV-NL63 LLC-MK2 NP and GeneBank accession number NC_005831 (Table 25). 
Table 25: Sequence comparison between GenBank NC_005831, HCoV-NL63 CaCo-2 LD and LLC-MK2 NP. 
Position is based on the GenBank entry NC_005831. Yellow background: CaCo-2 LD matches LLC-MK2 NP but 
not NC_005831; green background: CaCo-2 LD matches NC_005831 but not LLC-MK2 NP, red background: 
CaCo-2 matches none. * double peaks, a smaller C-peak is also visible, nt = nucleotide; aa = amino acid. 
  NC_005831 LLC-MK2 NP CaCo-2 LD 
position gene nt aa nt aa nt aa 
327 nsp1 C Serine T* Leucine T Leucine 
2956 nsp2 T Proline A Proline A Proline 
2977 nsp2 T Alanine A Alanine A Alanine 
4740 nsp3 C Alanine C Alanine T Valine 
10565 nsp6 T Serine T Serine C Proline 
12442 nsp11/12 G Alanine G Alanine G/T * Alanine/Serine 
12477 nsp12 C Cysteine T Cysteine T Cysteine 
16875 nsp13 C Threonine T* Isoleucine C Threonine 
17621 nsp14 C Phenylalanine C Phenylalanine T Serine 
21162 ORF2 (spike) C Phenylalanine C Phenylalanine T Proline 
21217 ORF2 (spike) C Serine C Serine T Phenylalanine 
21390 ORF2 (spike) T Leucine T Leucine G Valine 
22525 ORF2 (spike) C Alanine T Valine C Alanine 
23466 ORF2 (spike) C Glutamine A* Lysine C Glutamine 
 
The sequence of HCoV-NL63 CaCo-2 LD retained four mutations of its parental LLC-MK2 
NP virus stock (yellow, Table 25). Three of those were silent mutations. All mutations were 
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located in the ORF 1a/b. Interestingly three of the mutations found in the LLC-MK2 NP virus 
stock were reverted to the original NC_005831 sequence in CaCo-2 LD (green, Table 25). 
However, two of those mutations in LLC-MK2 NP had underlying bases that corresponded to 
NC_005831. 
Seven mutations of CaCo-2 LD were new, non-silent and corresponded to neither LLC-MK2 
NP, nor NC_005831 (red, Table 25). Four of the mutations were located in the ORF 1a/b and 
three in the spike (ORF 2) region. The mutations at position 327, 12442, 17621 and 21217 
were found exclusively in HCoV-NL63 CaCo-2 LD when compared to other laboratory strains 
(van der Hoek et al. 2004; Donaldson et al. 2008) and clinical isolates (Fouchier et al. 2004; 
Pyrc et al. 2006) 
 
Sequencing 5’ and 3’ ends of HCoV-NL63For the sequence verification of the 5’ and 3’ end 
of the viral genome a RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE, 
see 2.2.1.19) was carried out. The sequence of the 3’ end complied with the sequence data 
from the GenBank entry for HCoV-NL63 Amsterdam 1 (NC_005831). The sequencing results 
of the 5’RACE indicated an additional guanidine at the most proximal 5’ end of the genome. 
This finding was concordant to the sequence data from another human coronavirus NL63 
strain associated with pneumonia (GenBank accession number AY518894) that was isolated 
simultaneously in 2004 by R. Fouchier and coworkers (Fouchier et al. 2004). The additional 
guanidine was thus included into the primer design for the 5’ end of the full-length HCoV-
NL63 cDNA clone.  
3.7 Cloning strategy 
The cloning strategy for the full-length HCoV-NL63 cDNA clone was based on the gradually 
assembly of the full-length cDNA genome using a pBelo vector backbone. pBelo BACs have 
proven to allow for stable integration and modification of full-length coronavirus cDNA 
genomes (e.g. SARS CoV).  
The full-length HCoV-NL63 genome was divided into seven subfragments by means of 
naturally occurring restriction sites. Unique restriction sites were preferred. These sites 
ideally had to be absent from the sequence of the vector backbone. Available restriction sites 
allowed the identification of fragments from two to seven kilobase pairs in size, as illustrated 
in Figure 14. However a few multiple occurring restriction sites had to be used and deleted 
on subclone level before further assembly of the full-length HCoV-NL63 cDNA clone. The 
division of the full-length HCoV-NL63 cDNA genome into subfragments also enabled other 
sequence modifications like introduction of mutations on the subclone level. The cloning 
strategy, including necessary sequence alterations, is summarized in Figure 14. 
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Figure 14: Schematic overview of the full-length recombinant HCoV-NL63 cloning strategy 
Map of the full-length recombinant HCoV-NL63 clone (rNL63 wt). Drawn to scale using Lasergene SeqBuilder. 
Subclone fragments A to F illustrated in yellow (A), green (B1 and B2), light blue (C), dark blue (D), pink (E) and 
red (F). pBelo BAC backbone illustrated in grey. Restriction sites used for the assembly of subclones and the full-
length-clone are shown in italic. Deleted restriction sites are presented in red. Additional sequences introduced by 
primers during the assembly of the clone are labeled green. 
 
Generally the HCoV-NL63 genome fragments were amplified from cDNA with PCR using a 
proofreading DNA polymerase, digested with restriction enzymes and ligated with modified 
pBelo BAC vector fragments (named “left” and “right arm”).  
A set of HCoV-NL63 genomic cDNAs served as templates for all subcloned PCR fragments. 
Primer for cDNA synthesis were chosen downstream of the subclones’ reverse primer. 
Usage of the same reverse primer for cDNA synthesis and PCR worked well for shorter 
fragments (< 2kb) in one-step RT PCR reactions, but frequently failed for longer fragments in 
a two-step RT PCR. 
The pBelo BAC cloning strategy required the modification of the pBelo BAC vector according 
to the characteristics of the HCoV-NL63 cloning strategy. This modified vector backbone was 
derived from pBelo as described in 2.2.1.22. Additionally an HCoV-NL63 specific linker had 
to be introduced for the construction of subclones and the sequential assembly of the full-
length clone. This procedure is described in detail below (3.7.1, 3.7.2, 3.7.3). 
The resulting pBelo BAC vector contained a single EcoRI site located in the chloramphenicol 
resistance gene. As the screening of E. coli clones was always performed under antibiotic 
pressure, the assembly of the clones often included a digestion with EcoRI leading to a 
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disruption of the chloramphenicol resistance gene. This strategy assured low background of 
E. coli clones carrying i.e. plasmids with wrong orientation or consecution of the single 
fragments or missing plasmid parts. The risk of generating false-positive E. coli clones was 
additionally reduced by the dephosphorylation of plasmid parts. As at least one 
phosphorylated plasmid end is necessary for a successful ligation (2.2.1.20), a religation is 
circumvented by dephosphorylation. Generally the plasmid fragments with either the intact 
chloramphenicol resistance gene or the major part of the resistance gene were 
dephosphorylated prior to gel purification and ligation. 
Ligation, transformation and screening of E. coli clones was always done as described in 2.2 
Methods. Screening of E. coli clones always comprised the analysis of the pBelo BAC size 
by gel electrophoresis, a verification of size and pBelo BAC integrity using PCR and 
sequencing of PCR products. These procedures are not mentioned again for every 
construction step depicted below. 
3.7.1 Construction of the HCoV-NL63-modified vector backbone 
The restriction sites of AatII, MluI, EcoRI and NotI were essential for the assembly of all 
pBelo BAC based subclones and the full-length clone (see Figure 15). A MluI site was 
introduced with the most 5’ end forward primer (NL63T7fwd +pspom Mlu), including also the 
T7 promoter sequence and a PspOMI restriction site. The AatII site and a NotI site were 
already present in the MCS of pBeloAd4, the AatII site was located a few bases upstream of 
the NotI site. pBelo dNco3 contained a single NotI site, the MCS was absent.  
The first subclone was generated to achieve a modified vector backbone containing the 
restriction sites in the correct order (MluI, AatII, NotI) and to introduce the MluI site as well as 
the T7 promoter. This subclone served as a backbone for the assembly of all HCoV-NL63 
subclones. It was built by assembling parts of pBelodNco3, pBeloAd4 and the first 500 base 
pairs of the HCoV-NL63 genome. The assembly is illustrated in Figure 15. 
All three fragments were ligated in one single reaction, the resulting pBelo BAC was 
designated A0 (Figure 15). 
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Figure 15: Construction of the modified pBelo BAC for cloning of the full-length HCoV-NL63 genome.  
A: Additional restriction sites were added to the PCR product using extended primer. Template: cDNA from full-
length RNA of HCoV-NL63 stock LLC-MK2 NP. Forward primer (green) contains recognition sites for PspOMI, 
MluI and T7. Reverse primer (red) contains an AatII restriction site. The PCR product generated with these 
primers contains a PspOMI, MluI and T7 site at its 5’end and an AatII site at its 3’end. B: The “left arm” of the 
vector backbone was amplified from pBelodNco3 using pBelo790F as forward and pBeSCfwd as reverse primer. 
The resulting 6.8 kilobase pair PCR product enclosed the unique NotI and EcoRI restriction sites. The “right arm” 
of the vector backbone was amplified using pBeSCrev as forward, pBelo1290R as reverse primer and pBeloAd4 
as template. The length of the resulting PCR product was approximately 900 base pairs; it contained the MCS 
with the unique AatII and an additional NotI recognition site and parts of the chloramphenicol resistance gene, 
containing the unique EcoRI site. C: The PCR products were digested with: EcoRI and NotI (left arm), PspOMI 
and AatII (HCoV-NL63 A0), AatII and EcoRI (right arm). NotI and PspOMI have different recognition sites but 
digestion leads to matching overhangs. Ligation of these matching overhangs leads to the deletion of both, the 
NotI and the PspOMI site. Therefore ligation of the two vector arms (left and right) and the HCoV-NL63 insert A0 
led to a clone with deleted NotI and PspOMI sites at the left arm-HCoV-NL63-junction. AatII and EcoRI restriction 
sites were not modified. The resulting clone (A0) contained all required unique restriction sites in the correct 
consecution (MluI – AatII – NotI – EcoRI). 
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The following construction of the subclone A0F introduced the 3’ end of the HCoV-NL63 
genome into the pBelo backbone and thus enabled the insertion of the remaining HCoV-
NL63 genome in between the 3’ and the 5’ ends of the cDNA genome. 
Based on the subclone A0, containing the 5’ end of the HCoV-NL63 genome, the AatII and 
NotI sites were used to introduce the F fragment containing the 3’ end of the genome into the 
plasmid. The right arm was amplified as described for subclone A0. Digestion was done with 
EcoRI and NotI. The left arm was amplified using pBeSCfw and pBelo790F for priming and 
subclone A0 as template, creating a PCR product containing the A0 fragment and the major 
part of the vector backbone. Digestion was done using EcoRI and AatII.  
The insert was amplified from cDNA with primers NL 25644 F +Aat and NL27553R+20t+NotI; 
introducing a novel NotI site downstream of the poly(A)tail at the 3’ end as well as a novel 
AatII site for ligation with the A0 fragment. All three fragments were ligated in one single 
unidirectional ligation reaction of the compatible ends. The resulting BAC was designated 
A0F (see Figure 16).  
 
 
Figure 16: Construction of subclone A0F. 1: PCR products used for the assembly of subclone A0F. A: 
fragment F, B: right arm of pBelo, C: left arm of pBelo. These PCR products were purified using 
phenol/chloroform extraction as described in 2.2.1.5, digested and dephosphorylated (B: right arm) as described 
in 2.2.1.20, and purified again using alcohol precipitation as described in 2.2.1.5.. 2: Preparative agarose gel, 
stained post-run according to 2.2.1.6, photographed after excision of nucleic acid fragments corresponding to the 
correct size (A: fragment F with a size of 1.9 kb, B: right arm with a size of 0.6 kb and C: left arm with a size of 7.5 
kb) for assembly of subclone A0F. 3: Positive subclone A0F with a size of 9.5 kb. Molecular weight markers: 1&2: 
GeneRuler 1 kb DNA Ladder, 3: Supercoiled DNA Ladder, see 2.1.11. 
 
This subclone was later assembled to subclone AF, which was essential for the construction 
of the full-length clone by combination of the sequentially assembled HCoV-NL63 cDNA 
subclones. 
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3.7.2 Construction of the subclones A- E 
The first subclones to be assembled were simultaneously subcloned into pBelo BAC and 
pSMART (2.2.1.22). For the subcloning using the pSMART vector backbone, a subset of 
phosphorylated primers was designed enclosing the chosen restriction sites for the future 
assembly of the subclones into a pBelo BAC-based full-length clone. The phosphorylated 
PCR products were then directly ligated to the dephosphorylated pSMART vector backbone, 
thus omitting the restriction and dephosphorylation steps needed for the pBelo BAC cloning 
strategy. 
For the subcloning into pBelo BAC all fragments were amplified using a proofreading 
polymerase (see 2.2.1.11 and 0). The PCR products were purified by either 
phenol/chloroform extraction (2.2.1.5) or the bead-based Ampure system (2.2.1.3).  
A set of genomic HCoV-NL63 cDNAs served as template for the amplification of insert DNA 
fragments, modified pBelo BAC plasmid DNA served as template for the amplification of the 
right and left vector arm.  
All fragments were digested with appropriate restriction enzymes for unidirectional ligation 
and partially dephosphorylated (see 2.2.1.20), purified and ligated according to 2.2.1.21. 
Figure 17 shows amongst others an example of the pBelo BAC based cloning of subclone 
B2 with a two-step ligation strategy.  
 
Figure 17: Ligation intermediates and subclones. 1: Ligation intermediates visualized using a preparative gel. 
Fragments for the two step assembly of the subclones B1, B2 and E. Ligation of the pBelo right arm with B1 (only 
the 0.6 kb fragment of the pBelo right arm is visible), B2 (upper arrow: ligation product with the correct size, 
middle arrow: fragment B2 sized 5 kb, lower arrow: pBelo right arm) and E (upper arrow: ligation product with the 
correct size, middle arrow: fragment E sized 4.2 kb, lower arrow: pBelo right arm). Molecular weight marker: 
GeneRuler 1 kb DNA Ladder (see 2.1.11) 2: Isolated plasmid DNA from the construction of subclone B2. 
Screening for positive clones from a one-step ligation of all three fragments (B2, right arm, left arm), the first of the 
two plasmid DNAs has the correct size of 11.9 kb. Molecular weight marker: Supercoiled DNA Ladder, see 2.1.11. 
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Following this strategy the insert was first ligated to the right arm of pBelo, excised from the 
agarose gel, purified and then ligated to the left arm of pBelo. After this second ligation the 
ligation reaction was added to competent E. coli cells. Transformation was done either 
chemically or using electroporation as described in 2.2.1.22. However, the assembly of the 
different subclones a one-step ligation strategy with all three fragments in one ligation 
reaction usually resulted in more E. coli colonies with more positive clones, respectively. 
Compared to the pBelo BAC cloning, the ratio of empty vectors was higher using the 
pSMART cloning kit. Therefore further assembly of subclones was exclusively done using 
pBelo BAC. 
3.7.2.1 Construction of subclone A 
The fragment A was first cloned into pSMART and subsequently into pBelo A0F (3.7.1).  
Using the pSMART kit the fragment A was ligated to a pSMART low copy vector carrying a 
kanamycin resistance gene after being amplified by PCR using Phusion polymerase with the 
phosphorylated primers 350F and 4000R_Aat, covering the HCoV-NL63 genome from bases 
350 to 4053 (position from GenBank entry NC_005831). Two of 16 clones were positive 
(Figure 18), showing a size of approximately 6 kb. This corresponded to the size of the 
vector (2 kb) plus an insert of approximately 4 kb. 
 
Figure 18: Fragment A in pSMART 
Agarose gel electrophoresis (TAE, 0.8%) of plasmids prepared from single colonies numbered 1-16. M: 
Supercoiled DNA ladder 2-10 kb (Promega). Empty vectors had a size of approximately 2 kb. Plasmids from 
clones number 4 (upper lane) and number 11 (lower lane) migrated at the height of the 6 kb band. They were 
considered as putative positive because the size was corresponding to vector (2 kb) including an insert (4 kb). 
 
Sequencing results of the positive clones showed a point mutation at position 327 
(NC_005831), the correction of this mutation was done after ligation to A0F in the subclone 
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AF (see 3.7.3.1). 
3.7.2.2 Construction of subclone B1 
The first approach for the cloning of fragment B1 was done generating a PCR product with 
phosphorylated primers NL3716F and NL7520R+AatII and using the pSMART kit. 29 clones 
were screened and no positive clones were found. In parallel, directed cloning into a pBelo 
vector was tested. For this approach Fragment B1 was amplified by Phusion polymerase 
PCR from cDNA with the primers NL3716FplusMluI and NL7520R_2+AatII yielding a PCR 
product from base 3716 to 7543 (position from GenBank entry NC_005831) with introduced 
MluI and AatII restriction sites at the 5’ and 3’ end, respectively. The PCR product was 
digested with MluI and AatII. For the ligation the left arm was amplified from subclone A0 with 
pBeSCfw and pBelo790F, and the right arm was amplified from pBeloAD4 with pBeSCrev 
and pBelo1290R. Both arms were digested with EcoRI, the left arm additionally with MluI and 
the right arm with AatII. After gel purification the fragment B1 and the two arms were ligated 
to a plasmid sized 10.7 kb and further treated as described in 3.7.3. The cloned B1 fragment 
showed 100% identity with the reference sequence. 
3.7.2.3 Construction of subclone B2 
Fragment B2 was amplified by Phusion polymerase PCR from cDNA with the primers 
NL7430FplusMluI and NL 12460 R +Aat yielding a PCR product from base 7426 to 12473 
(position from GenBank entry NC_005831) introducing the same restriction sites as 
described for subclone B1. PCR and digestion was done according to subclone B1. The 
insert of the 11.9 kb sized plasmid was identical with the reference sequence. 
3.7.2.4 Construction of subclone C 
The fragment C had a size of only 2.3 kb and was the first fragment to be subcloned. The 
PCR product was amplified using primers S12300plusMluI and NL 14629 R, the amplification 
product comprised the bases 12264 to 14629 of NC_05831. The MluI site was introduced by 
the forward primer, an AatII recognition site is located naturally in the HCoV-NL63 genome at 
position 14573-14578 (NC_005831). It was digested with MluI and AatII and ligated, as 
described for fragment B1 and B2, to the digested left and right arm of subclone A0 and 
pBeloAD4, respectively. The only positive clone had a size of 9.2 kb and showed a silent 
marker mutation at position 12477 and an insertion of one additional A at position 14117 
(NC_005831). This insertion could not be found when performing and sequencing a one-step 
RT PCR from the original genomic RNA. Therefore it had to be PCR acquired and was 
corrected (see 3.7.2.7). 
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3.7.2.5 Construction of subclone D 
Fragment D, sized 7.3 kb, was the largest fragment to subclone. Due to the lack of 
alternative restriction sites, this fragment had to be amplified from cDNA in one continuous 
sequence. Several sets of cDNA primers and cDNA reaction setups as well as subsequent 
PCR reactions were tested and optimized. Finally, a PCR using a proofreading polymerase 
(Herculase) with an increased input of cDNA yielded sufficient amounts of the desired 
fragment without any potentially interfering side products (see Figure 19 lanes five to eight).  
 
 
Figure 19: PCR product of fragment D – optimization of PCR reactions with cDNA templates. 
PCR products of fragment D amplified with a proofreading polymerase (Herculase) according to 0. Different 
cDNAs and increasing volume of cDNA template were used for the optimization of the PCR reaction. M: 
GeneRuler 1 kb DNA Ladder. Lane 1-4 PCR products using cDNA generated with primer 25873R_2 and following 
input volumes of cDNA: lane 1: 4 µl, lane 2: 6 µl, lane 3: 8 µl, lane 4: 10 µl. Lane 4-8 PCR products using cDNA 
generated with primer 22251R and following volumes of cDNA template: lane 5: 4 µl, lane 6: 6 µl, lane 7: 8 µl, 
lane 8: 10 µl.  
 
For the generation of the 7.3 kb PCR product the primers NL 14507 F and NL 21824 R 
plusNotI were used. The PCR product was concordant to position 14507 to 21824 of the 
reference sequence NC_05831. The PCR product was digested with AatII, naturally located 
at position 14573-14578 (NC_005831) of the HCoV-NL63 genome and NotI, which site was 
introduced by the reverse primer during PCR. 
The construction of the pBelo arms differed from the strategy of subclones B1, B2 and C 
regarding the restriction enzymes used. All the subclones containing sequences located 
downstream of the HCoV-NL63 genomes’ AatII site used a left arm amplified from A0 with 
the primers pBeSCfw and pBelo790F digested with EcoRI and AatII. The right arm was 
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amplified from A0 or pBeloAD4 using the primers pBeSCrev and pBelo1290R. It was 
digested with NotI and EcoRI.  
For fragment D a two-step ligation was necessary, because the strategy of simultaneous 
ligation of three fragments failed. 
For a two-step ligation, the fragment D was first ligated to the left arm, gel purified and 
afterwards ligated to the right arm, yielding a plasmid sized 14.6 kb. Positive clones had a 
non-silent point mutation at position 16875 (NC_005831, see Table 23) changing Threonine 
to Isoleucine. This point mutation was corrected (see 3.7.2.7). 
3.7.2.6 Construction of subclone E 
Fragment E was amplified from cDNA by Phusion polymerase PCR using primers S 
21637+Aat and NL 25873 RplusNotI. The PCR product was processed as described for 
fragment D. 
The 11.6 kb sized positive clones had two non-silent point mutations at position 22525 and 
23466 (NC_005831, see Table 23), both mutations were corrected (3.7.2.7). 
3.7.2.7 Correction of the subclones 
Corrections were done using the Phusion (2.2.1.16) and QuickChange II (2.2.1.17) site 
directed mutagenesis kits. Primers were designed according to the manufacturers’ 
recommendations and re-designed when the generation of PCR products or clones failed.  
Correction of subclone C 
The insertion in subclone C was corrected using the phosphorylated primers NL63-pB-C-
mut2002F and NL63-pB-C-mut2002R2 and the QuickChange mutagenesis kit. Single 
colonies were analyzed for the correct sequence at position 14117 (NC_005831). 
Correction of subclone D 
The point mutation at position 16875 (NC_005831) in subclone D was corrected using the 
Phusion site-directed mutagenesis kit with phosphorylated primers D2936corFw and 
D2936corRev. The annealing temperature had to be lowered to 58°C for the generation of a 
PCR amplicon. The PCR product was successfully ligated, transformed and yielded positive 
clones with a correct sequence. 
Correction of subclone E 
For the correction of subclone E both point mutations were changed in parallel using the 
Phusion site-directed mutagenesis kit. In one reaction, the point mutation at position 22525 
(NC_005831) was corrected with primers pB_E_mut1562F_2 and pB_E_mut1562R_2, in a 
second reaction the mutation at position 23466 (NC_005831) was corrected with primers 
pB_E_mut2503F_2 and pB_E_mut2503R_2. The mutagenesis PCRs were ligated 
transformed and resulting colonies were screened for positive clones with the correct 
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sequence.  
Clones with the correct sequence, one corrected at position 22525 and the other at position 
23466, were digested with BsrGI. This enzyme had a recognition site at position 23272 to 
23277 from HCoV-NL63 (NC_005831) and in the repE gene of the pBelo backbone. Ligation 
of the fragment parts containing the corrected point mutations resulted in clones with a 
sequence according to GenBank Accession Number NC_005831 at position 22525 as well 
as 23466. 
3.7.3 Assembly of the subclones 
For the generation of the full-length cDNA clone the subclones were gradually assembled to 
bigger subclones as described below, finally resulting into two subclones containing the 5’ 
and the 3’ half of the HCoV-NL63 cDNA genome (subclone ABC and ADEF, see Figure 20). 
These two subclones were joined and resulted into the full-length HCoV-NL63 clone. 
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Figure 20: Assembly of subclones and full-length HCoV-NL63 clone. 
From A to F: HCoV-NL63 genome, the resulting cloning strategy and the effective assembly of the full-length 
clone. A: Illustration of HCoV-NL63 genome and the subgenomic mRNAs (Pyrc et al. 2007). B: PCR products 
generated from a set of cDNAs from full-length RNA of HCoV-NL63 stock LLC-MK2 NP. PCR products for 
fragments A, B1, B2 and C were generated using forward primers with an additional MluI site and reverse primers 
with an additional AatII site. PCR products for fragments D, E and F were generated using forward primers 
carrying an additional AatII site and reverse primers with an additional NotI site. C: Cloning strategy in scale of the 
HCoV-NL63 genome (see schematic overview in A). Existing unique (except of BamHI) restriction sites for the 
assembly are highlighted. PCR products containing the genome fragments are illustrated in different colors 
(yellow: A0 and A, light green: B1, dark green: B2, blue: C, violet: D, pink: E, red: F). Construction of the modified 
pBelo BAC A0 is depicted in Figure 15. D: Construction of the subclones, using the modified pBelo BAC A0 as 
vector backbone (Exception: subclone A was initially cloned into pSMART). PCR products and BAC inserts are 
illustrated in their corresponding colors. Restriction enzymes used for the digestion of the PCR products and the 
PCR generated vector arms are depicted in italics, restriction sites used for the further assembly are highlighted. 
E: Assembly of subclones containing a single fragment up to half-length clones (ABC and ADEF). For the 
assembly plasmids were digested and ligated; restriction enzymes employed are shown in italics. Fragments for 
the assembly of subclone ADEF were generated using PCR and digestion, the ligation of FauI and KasI restricted 
fragments led to the deletion of the KasI/BsaHI site (black diamond) connecting fragments E and F. F: Assembly 
of the full-length HCoV-NL63 clone using BsaHI and EcoRI restricted subclones ABC and ADEF. 
 
3.7.3.1 Assembly of subclone AF 
For the construction of the subclone AF, fragment A was amplified from the pSMART clone 
(3.7.2.1) using vector primers SL1 and SR2 and Phusion DNA polymerase (2.2.1.11). This 
PCR product was digested with SphI and AatII.  
The receiving vector backbone including the A0 and the F fragment was prepared in two 
ways: The first method comprised preparation of plasmid DNA (Midi scale) from subclone 
A0F (3.7.1), followed by an EcoRI digestion. The reaction was precipitated and washed, 
resuspended, split and a second digestion with either SphI or AatII followed, leaving a left 
arm sized 6.6 kb containing the 5’ end (A0) and a right arm sized 2.5 kb containing the F 
fragment.  
The second method used a PCR with the primer pairs pBeSCfw-pBelo790F for the left arm 
and pBeSCrev-pBelo1290R for the right arm. The PCR products were digested with SphI 
and EcoRI for preparation of the left arm; the right arm was digested with AatII and EcoRI. 
Sizes of the digested fragments were 6.6 and 2.5 kb, respectively. 
The digested plasmids and PCR products were gel-purified and ligated in two separate 
reactions, either the plasmid-based left and right vector arms together with the A insert in a 
two-step ligation reaction, or the PCR-based arms together with the A insert in a one-step 
ligation reaction. The ligation reactions were transformed into chemically competent E. coli 
cells (stbl3); single colonies were isolated and screened using PCR as well as performing 
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plasmid preparations and agarose gel electrophoresis.  
Interestingly the ligation of PCR products in a one-step ligation reaction proved to be much 
more effective than the ligation with vector arms originally prepared and digested from 
plasmids and ligated in two steps (Figure 21).  
 
 
Figure 21: Screening of AF subclones. Screening of isolated plasmid DNA for positive clones from different 
ligation strategies: AF*: ligation of fragment A and pBelo right arm first, then addition of pBelo left arm containing 
fragment F, all clones are negative and have a size of 9.5 kb, corresponding to the size of subclone A0F. AF**: 
one step ligation of three digested fragments (fragment A, pBelo right arm, pBelo left arm containing fragment F). 
All fragments were initially obtained by using PCR. All clones have a size of 13 kb, corresponding to the 
calculated size of subclone AF. Molecular weight marker: Supercoiled DNA Marker Set, see 2.1.11. 
 
In Figure 21 the correct size of the screened plasmid DNA from clones of the one step 
ligation (AF**) indicates a high efficacy of this method compared to the two step ligation (AF*) 
with no clones containing plasmid DNA of the correct size. 
Correction of subclone AF 
Three mutations were noticed in comparison to the reference sequence NC_005831, two of 
them silent. The non-silent mutation at position 327 (NC_005831) was corrected using the 
Phusion site-directed mutagenesis kit (2.2.1.16) with the primers NL63-pB-NLA3-mut494F 
and NL63-pB-NLA3-mut494R2.  
Deletion of AarI, NheI 
Three restriction sites of subclone AF were deleted to enable the cloning strategy depicted in 
Figure 20. The NheI digestion for the connection of fragment D and E required the deletion of 
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NheI sites in the fragments A and F (see Figure 14).  
Two Phusion site-directed mutagenesis kit reactions were carried out using subclone AF as 
template, one deleting the NheI site in fragment A, using primers ORF1a1b_delNhe_fw and 
ORF1a1b_delNhe_rev; one deleting the NheI site in fragment F using primers 
ORF6delNhe_fw and ORF6delNhe_rev. Plasmids were digested with EcoRI and BamHI and 
the parts of the subclones containing the deleted restriction sites were ligated. A subclone 
with deleted NheI sites in fragments A and F was chosen and used as template for other 
Phusion site-directed mutagenesis kit reactions, deleting the AarI site. Primers 
ORF1_delAar_fw2 and ORF1_delAar_rev2 were used for the PCR reaction. One of the 
positive clones was chosen and the insert (fragment A plus F) was sequenced in total. It 
showed to be concordant with the GenBank sequence NC_05831 except of the tolerated 
silent mutations (see HCoV-NL63 LLC-MK2 NP in Table 23) and the introduced mutations 
leading to the deletion of NheI and AarI restriction sites. 
Deletion of KasI 
The whole HCoV-NL63 cloning strategy depended on a final digestion with AatII and a 
ligation of the compatible ends thereof. As already described for subclone AF, the digestion 
and ligation of PCR products worked well using AatII, whereas the digestion and ligation of 
plasmid preparations was less effective (see 3.7.3.1). For the assembly of bigger subclones, 
the cloning strategy was changed in favor of BsaHI. This enzyme recognizes the AatII as well 
as the KasI site. Therefore the KasI site of fragment F had to be deleted.  
The modification was done in parallel to both subclones AF (described here) and ADEF 
(described below 3.7.3.6).  
A preparation of subclone AF plasmid was digested with NotI and BsaHI (see 3.7.3.6). This 
resulted in an 11 kb fragment containing the vector backbone and the fragment A, and two 
smaller fragments (1.8 and 0.15 kb). The two smaller fragments represented the digestion 
products of fragment F after cutting the AatII and the KasI site with BsaHI. The 11 kb 
fragment, also used for the construction of ADEF with deleted KasI, was ligated to the 1.8 kb 
fragment, joining the AatII and the KasI restriction sites. This slightly smaller subclone AF 
lacked a short stretch of the F fragment and joined the AatII and KasI site to a BsaHI site. 
Clones were first sequenced for the absence of the AatII and KasI sites and the presence of 
the BsaHI site and then in total. The plasmid was designated subclone AF “del”. 
3.7.3.2 Assembly of subclone AB1 
For the construction of AB1 preparations of the plasmids AFdel (3.7.3.1) and B1 (3.7.2.2) 
were used. The plasmids were digested with BamHI and BsaHI, yielding two fragments of 
12.6 and 0.2 kb for AF del and two fragments of 7.0 and 3.7 kb for B1. The 12.6 kb fragment 
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contained the sequence of fragment A, a part of fragment F and the vector backbone. The 
3.7 fragment contained fragment B1. They were ligated to a 16.3 kb pBelo BAC designated 
AB1. 
3.7.3.3 Assembly of subclone B2C 
For the assembly of subclone B2C plasmid preparations of subclone B2 (3.7.2.3) and C 
(3.7.2.4) were digested with EcoRI and BamHI. After complete digestion subclone B2 was 
separated in an 11.2 kb and a 0.7 kb fragment and subclone C in a 6.4 and 2.8 kb fragment. 
The 11.2 kb fragment contained fragment B2 and the left arm of the vector backbone and 
was ligated to the right arm of the vector backbone containing fragment C, resulting in a 
14 kb subclone B2C. 
3.7.3.4 Assembly of subclone DE 
The assembly of subclone DE was done using plasmid preparations of the subclones D and 
E. Both plasmids were digested with NheI and EcoRI. Fragment D was digested in two 
fragments sized 13.9 and 0.7 kb, for fragment E the sizes were 6.9 and 4.7 kb, respectively. 
The 13.9 kb part containing fragment D and the left arm of the vector backbone as well as 
the 4.7 kb part containing fragment E and the right arm of the vector backbone were ligated 
to the subclone DE sized 18.6 kb. 
3.7.3.5 Assembly of subclone BC 
For the assembly of subclone BC plasmid preparations of subclone B1 and subclone B2C 
were digested with PacI and EcoRI, yielding a 10.1 and a 0.6 kb fragment for B1 and a 7.7 
and a 6.4 kb fragment for B2C. The B1 and major vector backbone containing 10.1 kb 
fragment and the B2C containing 7.7 kb fragment were ligated to the resulting 17.8 subclone 
BC. 
3.7.3.6 Assembly of subclone ADEF 
As already described in 3.7.3.1, the digestion of plasmids with AatII was crucial for the 
cloning of the full-length HCoV-NL63 clone. Despite several changes in the reaction setup, 
no complete digestion of plasmids could be achieved. The changes comprised variation of 
enzyme units, proteinase K incubation before restriction, prolonged incubation times, 
digestion after linearization of the plasmid, different enzyme providers and a switch of the E. 
coli host. This finding was concordant to the observation made during the assembly of 
subclone AF, indicating an efficient digestion and ligation of PCR products in contrast to a 
poor digestion and ligation of plasmids (3.7.3.1). 
The only efficient solution was a change of the cloning strategy in favor of BsaHI. BsaHI 
(GR’CGYC) recognized the central AatII restriction site (GACGT’C) as well as the fragment E 
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to F linking KasI restriction site (G’GCGCC). Given that AatII and KasI were part of the 
original cloning strategy, with AatII being more essential, this switch necessitated the deletion 
of the KasI site.  
Deletion of KasI and the assembly of ADEF from the subclone AF and DE were done 
simultaneously. Three fragments were generated for the deletion of the KasI site:  
The first fragment comprised the F fragment and was amplified from subclone AF using the 
forward primer KasI_del_lang, introducing a G for a C in the KasI recognition site (GGCGCC 
 GGCGGC) and containing a 5’ proximal FauI restriction site. Primer pBelo1290R was 
used as reverse primer. The PCR product was digested with NotI and FauI, leaving a 1.8 kb 
fragment with compatible overhangs for the ligation with NotI and BsaHI digested DNA (see 
Figure 20). 
For the generation of the second fragment the DE subclone was digested with BsaHI, cutting 
at the AatII and the KasI site. The digestion resulted in two fragments, one containing mainly 
the vector backbone (7.5 kb) and the other containing the fragments D and E (11.2 kb).  
The third fragment was generated by the digestion of subclone AF with NotI and BsaHI, 
leading to a 11 kb fragment containing the vector backbone and the fragment A, and two 
smaller fragments (1.8 and 0.15 kb). 
All three fragments (1.8kb fragment F, 11.2 kb fragments DE and 11 kb pBelo BAC including 
fragment A) were ligated to subclone ADEF with a deleted KasI site in the F fragment (see 
Figure 14 and Figure 20). 
3.7.3.7 Assembly of subclone ABC 
For the construction of subclone ABC plasmid preparations of subclones AB1 and BC were 
used. The plasmids were digested using PacI and EcoRI, resulting in two 13.5 and 2.5 kb 
fragments regarding AB1. The bigger fragment comprised the major part of the vector and 
fragments A and B1. 
The BC plasmid was cut in a 7.7 and a 10.1 kb sized fragment. The former comprised 
fragments B2, C and the right arm of the vector; the latter contained fragment B1 and the 
bigger, left arm of the vector. The 7.7 kb fragment was ligated to the 13.5 kb fragment, and 
resulted in subclone ABC. 
3.7.3.8 Assembly of the NL full-length cDNA clone 
For the assembly of the full-length cDNA clone (Figure 14 and Figure 20) plasmid 
preparations of the subclones ADEF and ABC were digested with BsaHI and EcoRI. This 
resulted in a 13.6 and a 10.4 kb sized fragment for ADEF and a 20.9 and 0.6 kb sized 
fragment for ABC. The 13.6 kb fragment containing DEF and the right arm of the vector was 
ligated to the 20.9 kb fragment containing ABC and the left arm of the vector. In total 12 
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different ligation reactions with various fragments from different digestions were set up and 
over 200 clones were screened until one positive clone was found. Sequencing was 
concordant to GenBank entry NC_005831, except for the naturally occurring marker 
mutations (position 2956, 2977, 12477, see Table 23) and introduced restriction sites 
(position 1087, 1405, 25753, 26582, see Figure 14). The full-length recombinant HCoV-NL63 
clone was designated rNL63 wt (for wild type), see Figure 22 B. 
3.8 In vitro transcription (IVT) of full-length rNL63 and N gene 
The recombinant full-length clone was equipped with the previously introduced single cutting 
NotI recognition site behind the poly (A) tail, which allowed the linearization of the plasmid. 
The linearized DNA was purified and served as template for in vitro synthesis of capped RNA 
using the introduced T7 promoter and a T7-based transcription kit. For the initial 
transcriptions the mMESSAGE mMACHINE kit (Ambion) was used. Complying with the 
guidelines for optimization of yield for long transcripts, the GTP to Cap analog ratio was 
altered to approximately 1:1.  
According to Enjuanes et al. (Almazan et al. 2004; Schelle et al. 2005) the efficiency of initial 
replication in coronavirus reverse genetic systems is increased by cotransfection of 
nucleocapsid mRNA. Therefore the N gene was amplified from the full-length rNL63 wt 
plasmid using primers NL_N+SP6fw and NL_27553R+20trev. An SP6 promoter sequence 
was introduced within the forward primer sequence. The PCR product was purified and in 
vitro transcribed using a SP6-based transcription kit. 
After in vitro transcription, the capped RNAs were purified using phenol/chloroform and 
precipitated with isopropyl alcohol. The yield of RNA was increased notably when incubating 
the RNA/isopropyl alcohol mixture over night at -20°C. The RNA pellets were resuspended in 
15-30 µl nuclease-free water and quantified using photometry. RNA concentrations of 2 to 5 
µg/µl were obtained. 
Some of the transcripts were analyzed using conventional agarose gel electrophoresis with 
DEPC treated buffers and solutions (Figure 22). The HCoV-NL63 transcripts were compared 
to a SARS CoV transcript that has already been successfully transfected into BHK cells 
previously. All full-length transcripts presented a smear from high to low molecular weight, 
starting with a faint but unambiguous high molecular band, except for the overloaded lane 3 
(Figure 22).  
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Figure 22: In vitro transcripts of Coronavirus full genome and N. Plasmid preparation of rNL63 wt. 
A: In vitro transcripts (selection). M: High molecular weight DNA marker; lane 1: linearized HCoV-NL63 full-length 
plasmid rNL63 wt (arrow, 34.481 kb). Lane 2: in vitro transcribed and capped, functional SARS CoV RNA, arrow 
indicates the putative full-length RNA transcript. Lane 3-4: in vitro transcribed and capped HCoV-NL63 RNA; 
upper arrow indicates a putative full-length RNA transcript, lower arrows indicate distinct bands originating from 
either smaller or coiled RNA transcripts. Lane 5: 1:10 diluted capped HCoV-NL63 N RNA transcript, arrows 
indicating bands with higher and lower molecular weight or with different secondary structures (coiled, relaxed). 
B: Plasmid preparation of rNL63 wt. M: Supercoiled DNA Marker Set. rNL63 wt: upper band represents the 
supercoiled plasmid of rNL63 wt (approximately 35 kb), lower band represents linearized plasmid. 
 
The major difference between the transcripts of SARS CoV and HCoV-NL63 were distinct 
bands within the smear, clearly visible in the HCoV-NL63 transcripts (lane 3 and 4, Figure 
22). The N transcripts of HCoV-NL63 showed a faint additional band and smear of higher 
molecular weight (Figure 22, lane 5, upper arrow). 
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3.9 Transfection into mammalian cells 
For the transfection into mammalian cells, usually 10 µg in vitro transcribed and capped full-
length virus RNA was transfected together with 2 µg in vitro transcribed and capped N gene 
RNA. A successful transfection was achieved using a comparatively low concentrated full-
length HCoV-NL63 transcript of 1 µg/µl. 7.5 µg of full-length RNA were co-transfected with 
3.5 µg N gene RNA into LLC-MK2 as well as CaCo-2 cells. Transfection of N gene RNA 
alone served as negative control. The cells were mixed with the RNA, pulsed and seeded in 
cell culture flasks as described in (2.2.2.5). Flasks were sampled at days 0, 4, 7 and 9.  
3.10 Rescue of rNL63 wt 
The transfected cells were monitored by real-time RT PCR, detecting viral nucleic acids, and 
cytopathic effects (CPE) were monitored macro- and microscopically. Since only a fraction of 
the added RNA was internalized by the cells, the real-time RT PCR results (Figure 23) 
showed high values for HCoV-NL63 RNA on day 0. 
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Figure 23: Quantification of viral RNA from rNL63 wt in cell supernatant post transfection. 
Results of Light Cycler analysis from LLC-MK2 cell culture supernatant after transfection with rNL63 wt in vitro 
transcribed (IVT) RNA. Samples were taken on day 0, 4, 7 and 9 post transfection. Sampling on day 0 was done 
immediately after seeding the electroporated LLC-MK2 cells into a cell culture flask. RNA copies decreased 
between day 0 and day 4 due to degradation of excess IVT RNA in the cell culture supernatant. Concentration of 
virus RNA increased again at day 4, 7 and 9 to a maximum on day 9. Increase of RNA copies in cell culture 
supernatant samples represented an increase of recombinant virus particles. 
 
The RNA in the supernatant was degraded slowly; this effect is visualized by the decreased 
RNA value on day 4. Between day 4 and day 7 the recombinant virus replication increased 
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notably, the viral RNA concentration in the samples rose and equaled the value of day 0. 
Virus replication continued and exceeded the initial value at day 9. Virus replication was only 
detected in LLC-MK2 cells. The negative controls with exclusive transfection of N gene RNA 
remained negative; also the CaCo-2 cells transfected with full-length genome and N gene 
RNA did not show any measurable signs of virus replication. 
The RNA that was extracted from the samples was also used for the verification of the origin 
of rescued virus. This was done by analyzing the genetic properties like marker mutations, 
introduced for the deletion of restriction sites (see below).  
Cell culture supernatant containing the novel, recombinant virus was prepared as described 
for virus stocks (2.2.3.1) and stored at -70°C. A plaque purification assay was done using 
CaCo-2 cells (see 3.10.3).  
3.10.1 Proof of marker mutations 
The introduced marker mutations were verified in two different ways. First, the NheI site that 
was deleted in the A fragment (see 3.7.3.1) was evidenced by amplification and digestion of 
the PCR products originating from the virus HCoV-NL63 LLC-MK2 NP and the recombinant 
virus rNL63 wt. For this purpose the RNA from the rescued recombinant virus as well as 
some RNA from HCoV-NL63 LLC-MK2 NP were amplified in a one-step RT PCR with 
primers 1688R and 880F, sequenced, purified and digested with NheI. Figure 24 A and B 
show the electropherogram of the NheI site being functional for HCoV-NL63 LLC-MK2 NP 
(A) and deleted for rNL63 wt (B). In Figure 24 C, the first two lanes show the approximately 
800 bp product amplified from HCoV-NL63 LLC-MK2 NP without (lane 1) and with (lane 2) 
NheI restriction. The cleavage into two fragments sized 250 and 550 bp indicated clearly the 
presence of the NheI site. Lanes 3 and 4 show the 800 bp PCR product amplified from rNL63 
wt without (lane 3) and with (lane 4) NheI digestion, proving the absence of the NheI site and 
therefore the recombinant origin of the virus. 
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Figure 24: Verification of recombinant HCoV-NL63 (rNL63 wt) by sequencing and NheI digestion. 
One-step RT-PCR of RNA preparations from transfected (rNL63 wt IVT) and infected (wild type virus) LLC-MK2 
cell cultures was performed. PCR products were sequenced (see A and B). The deletion of the NheI restriction 
site was verified by restriction of the purified PCR product and succeeding gel electrophoresis (see C). 
A: Electropherogram of the wild type virus (HCoV-NL63 LLC-MK2 NP) sequence. PCR product was sequenced 
using primer 1154F. The sequence covers the functional NheI restriction site at base pair position 1403-1408 
(Reference sequence: Amsterdam 1, Accession No. NC_005831) boxed in green. B: Electropherogram of the 
recombinant virus (rNL 63 wt) sequence. PCR product and sequencing was done according to A. The deleted 
NheI restriction site is boxed in orange. C: NheI restriction of PCR products. M: GeneRuler 100 bp Plus DNA 
Ladder. Lane 1: 800 bp one-step RT PCR product of wild type virus (HCoV-NL63 LLC-MK2 NP). Lane 2: 800 bp 
one-step RT PCR product of wild type virus (HCoV-NL63 LLC-MK2 NP, see lane 1) after digestion with NheI, 
producing two 550 and 250 bp fragments. Lane 3: 800 bp one-step RT-PCR product of recombinant HCoV-NL63 
(rNL63 wt). Lane 4: 800 bp one-step RT PCR product of recombinant HCoV-NL63 (rNL63 wt, see lane 3) after 
incubation with NheI, the one-step RT PCR product remains 800 bp in size, the recognition site for NheI is 
deleted. 
 
The second evidence was given by sequencing the deleted AarI site in fragment A. For this 
purpose the RNAs from rNL63 wt as well as from HCoV-NL63 LLC-MK2 NP were amplified 
in a one-step RT PCR with primers 1471R and 398F, purified and sequenced in forward 
direction with primer 771F and in reverse direction with primer 1471R. Figure 25 shows the 
sequencing results for AarI. The sequence variation is boxed, showing an intact AarI 
recognition site for HCoV-NL63 LLC-MK2 NP. Concordant with the sequence of the full-
length clone, the results from sequencing the rNL63 wt virus showed clearly a “G” in the 
electropherogram, confirming it to be a recombinant virus with deleted AarI recognition site. 
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Figure 25: Verification of the AarI restriction site deletion in the recombinant HCoV-NL63 (rNL63 wt). 
One-step RT-PCR products from RNA preparations of transfected (rNL63 wt) and infected (wild type virus) cell 
cultures were sequenced using primer 771F. The sequence covers the functional and mutated AarI restriction site 
at base pair position 1086-1092 (Reference sequence: Amsterdam 1, Accession No. NC_005831). A: 
Electropherogram of wild type virus (HCoV-NL63 LLC-MK2 NP) with functional AarI restriction site boxed in 
green. B: Electropherogram of recombinant HCoV-NL63 (rNL63 wt) with deleted AarI restriction site boxed in 
orange. 
 
With these findings further tests were done to confirm the presence of viable recombinant 
virus. 
3.10.2 Immunofluorescence Assay (IFA) of rNL63 wt 
Virus replication of rNL63 wt was analyzed by detecting the expression of viral proteins in 
infected CaCo2 cell cultures using an immunofluorescence assay (2.2.4.2). The 
nucleocapsid and the matrix protein were successfully detected using Anti-N antibodies and 
Anti-M antibodies, as shown in Figure 26.  
The nucleocapsid protein was mainly detected in the cytoplasm of the infected CaCo-2 cells 
(Figure 26 A). The matrix protein was located around the nucleus, indicating a position in or 
close to the rough ER (Figure 26 B) and ERGIC as previously described (Muller et al. 2010). 
Therefore the presence of viable, recombinant rNL63 wt virus could be assumed. 
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Figure 26: Immunofluorescence Assay of recombinant HCoV-NL63 (rNL63 wt). 
Caco-2 cells were seeded on a 24-well plate and infected with recombinant HCoV-NL63 (rNL63 wt). Four days 
after infection cells were fixed with PFA (4%) for 15 min and permeabilized with 100% acetone for 10 min. 
Afterwards the cells were washed with PBS and then incubated with the primary antibody, diluted 1:100 in sample 
buffer at 37°C for 1 h. For the detection of the different viral proteins (M, N) peptide generated rabbit antisera 
(Muller 2007) were applied. Secondary detection was done with a rhodamine-conjugated goat-anti-mouse 
antibody at 37°C in a wet chamber for 30 min. Slides were mounted with DakoCytomation Fluorescent Mounting 
Medium and analyzed by fluorescent microscopy at a magnification of 400-fold. White bar represents 50 µm. A: 
CaCo-2 cells infected with rNL63 wt, primary antibody Rabbit Anti N serum 1:100, secondary antibody Anti-Rabbit 
Cy3. B: CaCo-2 cells infected with rNL63 wt, primary antibody Rabbit Anti M serum 1:100, secondary antibody 
Anti-Rabbit Cy3.  
3.10.3 Plaque purification 
As soon as viral replication could be detected and confirmed in the transfected cells, plaque 
purification was done, in order to minimize defective interfering particles and to gain a 
recombinant virus of high viability. 
Interestingly the recombinant virus showed extremely small plaques (Figure 27 B) compared 
to HCoV-NL63 LLC-MK2 NP (Figure 27 A). The plaques of the recombinant virus became 
visible after 7-10 days using agarose overlay. They were very hard to see either 
macroscopically or microscopically and plaque picking was difficult due to the small size. In 
the third round of plaque purification, the plaque morphology changed to bigger, visible 
plaques with HCoV-NL63 LLC-MK2 NP-like appearance (Figure 27 C). 
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Figure 27: Comparative plaque assay of wild type and recombinant HCoV-NL63. 
CaCo-2 cells were seeded on six-well plates and infected with wild type (HCoV-NL63 LLC-MK2 NP) and 
recombinant (rNL63 wt) virus. Infected cells were overlaid with 1.6% Avicel in DMEM and incubated at 37°C and 
5% CO2. On day 5 Avicel overlay was removed, cells were fixed with PFA (4%) for 15 min and stained with 
crystal violet solution for 15 minutes. A: Large and clearly visible plaques of wild type virus (HCoV-NL63 LLC-
MK2 NP). B: Very small and hardly visible plaques of recombinant virus rNL63 wt. White arrows indicate the 
location of the plaques. C: Large and clearly visible plaques of plaque purified rNL63 wt. 
 
After the third round of plaque purification using CaCo-2 cells, a virus stock was generated 
as described in (2.2.3.1); marker mutations were verified by sequencing a one-step RT PCR 
product from the virus stock as described in 3.10.1.  
A comparison of growth kinetic from plaque purified rNL wt and HCoV-NL63 CaCo-2 PP 
virus stocks showed a similar amount of viral RNA after 168 hours in cell culture supernatant 
of infected CaCo-2 cell cultures (Figure 28 A).  
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Figure 28: Quantification of viral RNA and plaque forming units (Pfu) from plaque purified rNL63 wt and 
HCoV-NL63 CaCo-2 PP in CaCo-2 cell culture supernatant. A: Results of Light Cycler analysis from CaCo-2 
cell culture supernatant after infection with rNL63 wt and HCoV-NL63 CaCo-2 PP virus stocks. Samples were 
taken after 6, 24, 48 and 168 hours. B: Comparative plaque assay of plaque purified rNL63 wt and HCoV-NL63 
CaCo-2 PP virus stocks. CaCo-2 cell cultures were seeded on six-well plates, infected with the respective virus 
stock and overlaid with Avicel as described above. Plaques were counted on day five. 
 
The slower growth of rNL 63 wt within the first 48 hours presumably resulted from the 
hundredfold difference in plaque forming units (Figure 28 B) of the virus stocks rNL wt and 
NL63 CaCo-2 PP used for the infection of the CaCo-2 cell cultures. Further plaque 
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purification of rNL63 wt could be performed to recover a virus stock with a similar titer 
compared to HCoV-NL63 CaCo-2 PP, resulting in similar growth kinetics. 
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4 Discussion 
4.1 Susceptibility studies with HCoV-NL63 and development of a plaque 
assay 
HCoV-NL63 is causative for up to 10% of common colds, especially in winter time, and can 
lead to hospitalization of predominantly young children and elderly persons. A major obstacle 
when working with HCoV-NL63 is that it replicates slowly and at relatively low titers in all 
current cell cultures, such as LLC-MK2 and Vero-B4 cells (Fouchier et al. 2004; van der 
Hoek et al. 2004). Because the virus contributes to a very weak and diffuse CPE in these 
cells, there is no cytopathic-based plaque assay available for HCoV-NL63.  
By conducting a broad-range susceptibility study using 12 cell lines, CaCo-2 cells were found 
to support HCoV-NL63 replication significantly better than hitherto used culture cells, 
especially when compared to the standard cultivation cell line LLC-MK2. A pronounced 
cytopathogenic effect was observed and was the foundation for the development of a plaque 
assay. Plaque assays make use of viscous overlays to cover cells immediately after 
infection, thus limiting virus spread and restricting virus growth to foci of cells at the sites of 
initial infection. If a virus  does not cause CPE in cells, these foci may be visualized by 
immunostaining (Battegay et al. 1991; Matrosovich et al. 2006).  
If viruses induce strong cytopathogenic effects, cells are lyzed and the generated plaques 
can be visualized by staining of the residual intact cells. Cytopathogenic plaque assays are 
compatible with high-throughput drug screenings (Leyssen et al. 2003; Leyssen et al. 2008) 
and allow virus plaque purification and subcloning of virus. This in turn is helpful in obtaining 
virus stocks with optimized infectivity, e.g., by decreasing the amount of defective interfering 
(di) particles that accumulate during serial passaging of CoV (Makino et al. 1984).  
It was interesting to note that the virus stocks obtained from LLC-MK2 as well as from CaCo-
2 cells had rather high RNA concentrations as opposed to their infectivities. PFU / RNA ratios 
were 2.92 X 10-6 for CaCo-2 PP and 2.45 X 10-6 for LLC-MK2 NP. This high excess of RNA 
over infectious units might be attributable to the virus harvesting procedure, possibly 
releasing nonpackaged RNA along with virus particles during freeze-thawing. Because PFU / 
RNA ratios were very similar for both stocks, it appeared unlikely that elimination of defective 
interfering particles had contributed to the gain of infectivity. 
After the additional purification of CaCo-2 adapted virus stock by ten consecutive limiting 
dilution series, several mutations of the HCoV-NL63 genome could be observed. Three of 
these mutations were identified in the spike region, which might represent an adaptation to 
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the CaCo-2 ACE2 receptor molecule and could contribute to the higher infectivity (3.1x106 
versus 1.3x105 PFU/ml) of the resulting virus stock HCoV-NL63 CaCo-2 LD. 
A recent publication describes the genomic changes of FIPV associated with viral adaptation 
at different tissue passage levels (Phillips et al. 2013). The complete genome of FIPV strain 
WSU 79-1146 was sequenced at passage 1, 8 and 50. An overall low mutation rate was 
calculated from the resulting amino acid differences. Nevertheless twenty-one amino acid 
differences were observed in the polyprotein 1a/ab between the different passages, nine in 
the structural proteins (spike, 3a, 3c, small membrane, nucleocapsid and 7a), respectively. 
Only one residue change was observed in the spike glycoprotein, which reverted back on 
subsequent passages and might help to explain the lack of differences in growth kinetic 
between the passages. In contrast to the observation made during the FIPV adaptation, in 
this work consecutive passages using CaCo-2 cell cultures led to an increase of infectivity, 
paralleled by three amino acid changes in the spike protein.  
Although the positions of the mutations in the spike gene (21162, 21217, 21390 in GenBank 
NC_05831) are located outside of the three described HCoV-NL63 ACE2 receptor binding 
domains (RBD) (Wu et al. 2009), two of them (21162 and 21390 in GenBank NC_05831) 
seem to be common loci for mutations, as they are also found in the strains Amsterdam 57 
and Amsterdam 496. The mutation at position 21217 (in GenBank NC_05831) exclusively 
occurs in strain HCoV-NL63 CaCo-2 LD. This finding could indicate a correlation between 
the change of the spike protein sequence and increased infectivity during adaptation to 
CaCo-2 cell cultures. 
Further mutations were observed in the nsp 3, 6, 11/12 and 14 genes. Two of them (nsp 
11/12 and 14) being unique for the CaCo-2 adapted strain, the other two mutations could 
also be observed in other circulating HCoV-NL63 strains. These mutations could either 
represent an adaptation to CaCo-2 cells or they occurred randomly. Interestingly Angelini et 
al recently published that transfection of SARS-CoV nsp 3, 4 and 6 induce double membrane 
vesicles (DMV) in HEK293T cell cultures (Angelini et al. 2013). The observed mutations in 
nsp 3 and 6 of the CaCo-2 adapted HCoV-NL63 CaCo-2 LD strain might influence the DMV 
formation and virus proliferation in CaCo-2 cell lines and therefore explain the higher 
infectivity compared to HCoV-NL63 LLC-MK2 NP. Another effect described by Eckerle et al. 
could contribute to the mutation rate of the CaCo-2 adapted HCoV-NL63. The nsp 14 
exonuclease activity is required for replication fidelity of MHV and SARS-CoV, the genetic 
inactivation of ExoN results in a 15-fold decrease of replication fidelity in MHV and a 21-fold 
increase in mutation frequency during replication of SARS-CoV in culture (Eckerle et al. 
2010). Although the SARS-CoV nsp 14-ExoN mutant viruses demonstrate stable growth 
defects, hitherto unknown effects of the mutation in the HCoV-NL63 CaCo-2 LD nsp 14 gene 
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might contribute to a higher mutation rate and faster adaptation to CaCo-2 cell cultures, 
including the higher infectivity described above. 
A stepwise introduction of the observed mutations into the full-length HCoV-NL63 cDNA 
clone and the analysis of their effects, i.e. using the novel plaque assay, could help to 
understand their function in the context of the complete viral genome. 
4.2 Establishment of a reverse genetics system for HCoV-NL63 
Reverse genetics systems are essential for the analysis and the understanding of viral gene 
functions. Additionally, reverse genetics systems based on relatively harmless common cold 
viruses like HCoV-NL63 could be used for gene delivery and chimeric vaccine development 
(Zust et al. 2007; Cervantes-Barragan et al. 2010; Ribes et al. 2010). Major advantages of 
coronavirus-based systems are that coronaviruses replicate exclusively in the cytoplasm, not 
involving mutagenic integrations into host genomes, and that they do not induce major 
immunological responses (replication in DMVs, expression of IFN antagonists) (Knoops et al. 
2008; Perlman et al. 2009; Knoops et al. 2010; McBride et al. 2012). Reverse genetics 
systems were described for SARS-CoV (Yount et al. 2003; Almazan et al. 2006; Pfefferle et 
al. 2009), MHV (Yount et al. 2002; Coley et al. 2005), TGEV (Almazan et al. 2000; Yount et 
al. 2000; Gonzalez et al. 2002), IBV (Casais et al. 2001), HCoV-OC43 (St-Jean et al. 2006), 
HCoV-229E (Thiel et al. 2001; Thiel et al. 2005), FCoV (Tekes et al. 2008) and recently also 
for HCoV-NL63 (Donaldson et al. 2008). The major challenge for all approaches was the 
cloning of the large coronavirus RNA genome.  
A reverse genetics system that is based on a BAC backbone, combined with a phage 
promoter-driven in vitro RNA synthesis from a cDNA full-length clone, and an efficient 
transfection of infectious RNA into the cytosol of susceptible mammalian cells is already well 
established in our workgroup for SARS-CoV (Pfefferle et al. 2009; Voss et al. 2009; Muth et 
al. 2010). The presented work describes the development of a similar reverse genetics 
system for HCoV-NL63. Several obstacles were encountered during this process paralleling 
the observations made by another group that published a reverse genetic system for HCoV-
NL63 in 2008 (Donaldson et al. 2008). 
Compared to other coronaviruses, the HCoV-NL63 genome shows an extremely low GC 
content of 34% (Pyrc et al. 2004) whereas U is highly represented (39%).  
Reasonable primer design for the construction of the subclones was complicated by the very 
low GC content of the HCoV-NL63 genome. In addition, some of the subclones had to be 
constructed from large RT PCR products, requiring excellent RNA and cDNA quality. 
Nevertheless, after optimization of the reverse transcription reaction, fragments as large as 
8 kb could easily be amplified from cDNA and subcloned into pBelo BAC.  
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The high U content of the HCoV-NL63 genome and of the nascent RNA during RNA 
synthesis from a cDNA template however, could hamper the in vitro transcription using T7 
polymerases. A stretch of the last three Us (position 20636-20643, Accession Nr. 
NC_005831) could possibly lead to a pause in transcription, as shown for T7 and T3 
polymerases (Lyakhov et al. 1998). After electrophoresis and staining of the in vitro 
transcribed full length RNA, multiple bands could be visualized (see Figure 22). This might 
indicate the formation of secondary structures, the premature termination of transcription, 
leading to a reduced yield of full-length RNA, or both. 
Another challenge was introduced with the unexpectedly low performance of AatII restriction 
using pBelo BAC as a template. Complete or nearly complete digestion could only be 
observed when using PCR products as template. Several approaches of troubleshooting 
experiments could neither improve nor explain the poor restriction efficiency of AatII using 
pBelo BACs as templates. Due to this circumstance, the whole cloning strategy had to be 
changed to a BsaHI dependent restriction and assembly strategy. With this change of the 
cloning strategy, more silent mutations had to be introduced into naturally occurring 
restriction sites for the successful assembly of a full-length clone.  
Despite of these drawbacks the full-length HCoV-NL63 genome could be assembled into six 
subclones and finally to a full-length cDNA clone. The subclones as well as the full-length 
clone provided a valuable stock for collaborating workgroups, because it superseded the 
laborious RNA extraction and cDNA synthesis steps and allowed easy amplification and 
modification of any genomic HCoV-NL63 sequence. 
As already mentioned above, HCoV-NL63 replicates at lower titers with minor growth rates 
when compared to SARS-CoV. The identification of CaCo-2 cells supporting HCoV-NL63 
replication was a first step and a basis to generate a reverse genetics system. However, 
CaCo-2 cells were difficult to electroporate and further optimization would be necessary to 
use those cells for the production of recombinant HCoV-NL63 virus. Therefore LLC-MK2 
cells were used for transfection of full length RNA despite of some difficulties in rescuing 
viable recombinant virus. 
It is remarkable, that the successfully rescued recombinant virus described in this work 
initially showed very small plaques (see Figure 27) indicating a weak cytopathic effect and 
replication. Only after several passages the original phenotype was displayed by rNL63 wt in 
the novel plaque assay. This supports the observation of another group that published a 
reverse genetics system for HCoV-NL63 (Donaldson et al. 2008). In their work three 
passages of the transfected LLC-MK2 host cells and cell supernatants were necessary until 
virus replication could be demonstrated. Considering both findings one could assume that, 
after transfection, LLC-MK2 may not support replication of recombinant virus sufficiently.  
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An interesting new approach could be found in the novel cell culture techniques of primary 
human respiratory epithelial cells used for the cultivation of some formerly unculturable 
respiratory viruses like HKU1 (Pyrc et al. 2010; Dominguez et al. 2013). Moreover human 
airway epithelium (HAE) cell cultures represent robust universal culture system that supports 
isolation, replication and comparison of all contemporary HCoV strains (Dijkman et al. 2013), 
including the novel Middle East respiratory syndrome (MERS) coronavirus (Kindler et al. 
2013). Rescue of recombinant virus might be improved by involving air-liquid interface cell 
cultures. 
The virus stock used as genetic background for the reverse genetics system described in this 
work showed seven mutations compared to NC_05831.2 (see Table 25); three of them had 
clearly an underlying HCoV-NL63 Amsterdam 1 sequence. All four non silent mutations were 
corrected according to the GenBank sequence. The sequence of HCoV-NL63 Amsterdam 1 
deposited at GenBank represents the sequence of a patients’ isolate (original Accession Nr. 
AY567487 (van der Hoek et al. 2004)) from the respiratory tract that was not yet adapted to 
growth in cell culture. This might explain the lag in replication of the recombinant virus after 
transfection seen in this work, as well as the need for several passages of the transfected 
host cells and their supernatant described by Donaldson et al (Donaldson et al. 2008). Using 
a viral genetic background adapted to transfectable cell lines like LLC-MK2 could strongly 
improve transfection efficiency and reduce the time to rescue of a recombinant virus. 
Another explanation for the difficulties in rescuing a viable recombinant virus could be found 
in silent or untranslated regions of the HCoV-NL63 genome, i.e. in the so called “codon pair 
bias” described by Coleman et al. (Coleman et al. 2008) or “long range RNA-RNA 
interactions” described by Guan et al. (Guan et al. 2012). With the introduction of silent 
mutations to enable the full-length cloning strategy, codons were possibly changed to 
naturally less frequently used codons, or the sequence inter-stem-loop domains were 
altered, leading to reduced rates of translation and therefore to a reduced probability of virus 
rescue. In addition to the naturally poor replication of HCoV-NL63 and all the other potentially 
interfering factors like premature termination of the transcription, inefficient linearization of 
the transcription template or insufficient transfection efficiency, the modification of the 
genome sequence in domains that were hitherto thought to be silent or uncritical, could be 
part of the explanation of the difficult virus rescue of recombinant HCoV-NL63.  
The importance of having coronavirus infectious cDNA clones at hand either for basic 
research or vaccine development has been stressed recently by the occurrence of novel 
Middle East respiratory syndrome (MERS) coronavirus (Danielsson et al. 2012; Zaki et al. 
2012; de Groot et al. 2013). Both SARS-CoV and MERS-CoV have shown how vulnerable 
we are to emerging coronaviruses (Braden et al. 2013; MMWR 2013). The high diversity of 
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coronaviruses in small mammals like bats and rodents (Gloza-Rausch et al. 2008; Drexler et 
al. 2010; Lau et al. 2010; Lau et al. 2012) as well as in birds (Woo et al. 2009; Woo et al. 
2012) together with the destruction of habitats make zoonotic introductions into the human 
population more likely (Patz et al. 2004; Jones et al. 2008; Field 2009; Jones et al. 2013).  
Creating attenuated coronaviruses by reverse genetics and using them as a tool for the 
delivery of antigens was already proven to be feasible for e.g. the development of attenuated 
IBV vaccine (Britton et al. 2012), for the immunization of mice against rotavirus using TGEV 
based vectors (Ribes et al. 2010) and the delivery of antigens and immunostimulatory 
cytokines to dendritic cells using MHV and HCoV-229E vaccine vectors (Cervantes-Barragan 
et al. 2010). Only one year after the emergence of MERS-CoV a recombinant MERS-CoV 
vaccine candidate was engineered using reverse genetics based on a cDNA clone (Almazan 
et al. 2013), in parallel an additional MERS-CoV reverse genetics system was published 
(Scobey et al. 2013). Both of them will allow for testing of therapeutical components, studying 
gene function and additional design of vaccine candidates. This rapid response to the threat 
of suddenly emerging viruses like SARS-CoV and MERS-CoV underlines the importance and 
usefulness of reverse genetics systems, including infectious cDNA clones for by now 
relatively harmless common cold viruses like HCoV-NL63. 
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5 Summary 
In 2004 a novel human coronavirus designated HCoV-NL63 was isolated in the Netherlands. 
The fact that it uses the same entry receptor as SARS-CoV could make HCoV-NL63 an 
important model for the identification of antiviral agents and the study of the pathogenesis of 
coronaviruses. The aim of this thesis was the construction and characterization of a novel 
reverse genetics system for HCoV-NL63. Initially the genome of the parental HCoV-NL63 
stain Amsterdam 1 was sequenced and different cell cultures were tested for susceptibility to 
identify suitable cell lines for propagation of HCoV-NL63. Based on the discovery of a highly 
susceptible cell line, CaCo-2, a novel plaque assay for HCoV-NL63 was established. This 
plaque assay was optimized with regards to medium and incubation times.  Repeated limiting 
dilution culture yielded a CaCo-2 adapted virus stock with increased replication and more 
pronounced plaque morphology as compared to the parental strain Amsterdam 1. The 
optimization of virus culture was essential for the construction and rescue of recombinant 
HCoV-NL63. Following a strategy of sequential assembly of pBelo BAC subclones, a stable, 
full-length infectious HCoV-NL63 cDNA clone was created. The cDNA clone served as 
template for phage promoter-driven in vitro synthesis of infectious RNA which is transfected 
into the cytosol of susceptible mammalian cells. Introduction of sequence alterations was 
enabled on subclone level. The straightforward subsequent construction of novel full-length 
cDNA clones enables future manipulations that help improving the understanding of viral 
gene functions. The novel reverse genetics system offers translational perspectives such as 
chimeric vaccine development and gene delivery. It will also be a valuable tool for future in 
vivo investigation of the pathogenesis conferred by HCoV-NL63. 
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6 Zusammenfassung (Summary in German) 
Im Jahr 2004 wurde in den Niederlanden ein neues humanes Coronavirus, HCoV-NL63, 
isoliert. Aufgrund der der Nutzung desselben zellulären Rezeptors wie SARS-CoV könnte 
HCoV-NL63 als Modellorganismus für die Identifikation antiviraler Substanzen sowie zur 
Untersuchung der Pathogenität von Coronaviren herangezogen werden. Ein infektiöser 
cDNA Klon ist für die Untersuchung der Rolle und Funktion viraler Gene und Proteine im 
Viruskontext essentiell. Daher wurde in der hier vorgestellten Arbeit die Konstruktion eines 
neuen reversen Genetiksystems für das humane Coronavirus NL63 angestrebt. Hierzu 
wurde zunächst das Genom des für die Konstruktion verwendeten Ausgangsstammes 
HCoV-NL63 Amsterdam 1 sequenziert. Zusätzlich wurden verschiedenen Zelllinien auf ihre 
Suszeptibilität für HCoV-NL63 untersucht. Mit der Zelllinie CaCo-2 konnte eine höchst 
suszeptible Zelllinie identifiziert werden, die für die Etablierung eines neuartigen Plaque 
Assays für HCoV-NL63 herangezogen werden konnte. Dieser Plaque Assay wurde 
hinsichtlich der Overlay-Medien und Inkubationszeiten optimiert. Außerdem wurde durch 
wiederholte Endpunkttitration des Ausgangsstammes HCoV-NL63 Amsterdam 1 ein auf 
CaCo-2 adaptierter Virusstamm erzeugt, der eine verstärkte Replikation und eine deutlichere 
Plaquemorphologie aufweist. Die erzielten Verbesserungen in der Viruskultur waren 
Voraussetzung für die Konstruktion eines neuartigen reversen Genetiksystems für HCoV-
NL63. Ein stabiler, die volle Länge des HCoV-NL63 Genoms beinhaltender cDNA Klon 
konnte erfolgreich konstruiert werden, indem pBelo BAC Subklone sequenziell 
zusammengefügt wurden. Dieser Klon diente als Matrize für phagenpromotoren-getriebene 
in vitro Synthese infektiöser RNA, die in das Cytosol suszeptibler Säugerzellen transfiziert 
wurde. Auf Ebene der Subklone können Sequenzänderungen eingeführt werden. Der 
folgende, vergleichsweise einfache Zusammenbau eines neuen, durchgehenden cDNA 
Klons ermöglicht eine vereinfachte Mutagenese des HCoV-NL63 Genoms. Das im Rahmen 
dieser Arbeit konstruierte reverse Genetiksystem für HCoV-NL63 wird ein wertvolles 
Hilfsmittel für die Entwicklung rekombinanter Vakzinen oder Transduktionstechniken 
darstellen, sowie die Untersuchung der Pathogenese der HCoV-63 Infektion erleichtern. 
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8 Appendix 
8.1 Abbreviations 
8.1.1 Viruses 
BCoV Bovine coronavirus 
BtCoV Bat coronavirus 
CMV Cytomegalovirus 
FIPV Feline Infectious Peritonitis Virus 
HCoV-HKU1 Human coronavirus HKU1 
HCoV-NL63 Human coronavirus NL63 
HCoV-229E Human coronavirus 229E 
HCoV-OC43 Human coronavirus OC43 
IBV Infectious Bronchitis Virus 
MHV Murine Hepatitis Virus 
PEDV Porcine Epidemic Diarrhea Virus 
SARS-CoV SARS coronavirus 
TGEV Transmissible Gastroenteritis Virus 
 
8.1.2 Others 
A Adenine 
aa Amino acid 
ACE2 Angiotensin converting enzyme 2 
Anti M Antiserum against M protein 
Anti N Antiserum against N protein 
ATCC American Type Culture Collection 
ATP Adenosine Triphosphate 
BAC Bacterial artificial chromosome 
BNI Bernhard-Nocht-Institute 
bp Base pair 
BSA Bovine Serum Albumin 
C Cytosine 
cDNA Complementary DNA 
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CIP Calf intestine alkaline phosphatase 
CMC Carboxymethyl-cellulose sodium salt 
CoV Coronavirus 
CPE Cytopathogenic effect 
Ct Threshold cycle 
CTP Cytosine Triphosphate 
C-terminus Carboxyl-terminus 
Cy5 Cyanine-5 
°C Degree Celsius 
d Day 
dATP Deoxyadenosine Triphosphate 
dCTP Deoxycytosine Triphosphate 
dGTP Deoxyguanosine Triphosphate 
ddNTP Dideoxynucleoside Triphosphate 
dNTP Deoxynucleoside Triphosphate 
dTTP Deoxythymidine Triphosphate 
DEPC Diethyl Pyrocarbonate 
DMEM Dulbecco’s Modified Eagles Medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
dpi Days post infection 
E. coli Escherichia coli 
e.g. 'exempli gratia' (for example) 
EDTA Ethylenediaminetetraacetic Acid 
ER Endoplasmic Reticulum 
ERGIC Endoplasmic Reticulum-Golgi Intermediate Compartment 
Fc Conserved part of an antibody 
FCS Fetal calf serum 
Fig. Figure 
FITC Fluorescein Isothiocyanate 
g Gram 
G Guanine 
GTP Guanosine Triphosphate 
gn Gravitational force (9.81 m/s²) 
ge Genome equivalent 
GFP Green fluorescent protein 
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h Hour 
HCoV Human coronavirus 
HRP Horseradish peroxidase 
ID Identification Data 
IFA Immunofluorescence Assay 
IPTG Isopropyl-Beta-d-Thiogalactopyranoside 
kb Kilobase 
kbp Kilobase pairs 
kDa Kilodalton 
L Liter 
LB medium Luria Bertani medium 
M Molar 
M protein Membrane protein 
MCS Multiple cloning site 
ME Beta-mercaptoethanol 
min Minute 
ml Milliliter 
mM Millimolar 
MOI Multiplicity of Infection 
MOPS 3-(n-Morpholino)Propanesulfonic Acid 
mRNA Messenger RNA 
µg Microgram 
µl Microliter 
n Non specified number 
NA Nucleic acid 
N protein Nucleocapsid protein 
n.d. Not determined 
Nm Nanometer 
NSP Non-structural protein 
nt Nucleotide 
N-terminus Amino-terminus 
OD Optical Density 
ORF Open reading frame 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
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PFU Plaque forming units 
pH “Potentia Hydrogenii “ Potential of Hydrogen - negative 10-base log 
(power) of the positive hydrogen ion concentration; measure of acidity 
pi Post infection 
RNA Ribonucleic acid 
rNTP Ribonucleotide triphosphate 
rpm Revolutions Per Minute 
RT Reverse Transcriptase 
rxn reaction 
s Second 
S protein Spike protein 
SARS Severe Acute Respiratory Syndrome 
sg mRNA Subgenomic mRNA 
S.O.C. Super optimal broth with Catabolite repression 
SS Superscript (RT Enzyme) 
T Thymine 
TAE Buffer Tris acetate EDTA buffer 
TE buffer Tris EDTA buffer 
Tm Melting temperature 
Tris Tris(Hydroxymethyl)aminomethane 
TRS Transcription regulating sequence 
U Uracil 
UTP Uridine Triphosphate 
UTR Untranslated region 
v/v Volume per volume 
V Volts 
VLP Virus like particles 
w/v Weight per volume 
WHO World Health Organization 
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